[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 291
1. Patel J, Deb R, Speake W, Macculloch TA: Primary small bowel liposarcoma (atypical lipomatous tumour) with myogenic differentiation. Sarcoma; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small bowel liposarcoma (atypical lipomatous tumour) with myogenic differentiation.
  • Primary small intestinal liposarcomas originating in the small bowel are uncommon with a generally poor prognosis due to the advanced stage at the time of diagnosis.
  • We describe a case of primary small bowel dedifferentiated liposarcoma presenting as a solid mass in the right iliac fossa.
  • The current case is unusual as the tumour seemingly originated from the bowel and the well-differentiated component was seen extensively infiltrating the bowel wall including the small bowel submucosa.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] World J Gastroenterol. 2008 Oct 14;14(38):5927-9 [18855997.001]
  • [Cites] Minerva Gastroenterol Dietol. 2000 Jun;46(2):119-22 [16498358.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • (PMID = 20706648.001).
  • [ISSN] 1369-1643
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2913843
  •  go-up   go-down


2. Wang C, Xu YQ: Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative? Gastroenterology Res; 2008 Dec;1(1):2-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative?
  • : Diphenyl dimethyl bicarboxylate (DDB) has been used in some countries as hepatoprotectant adjuvant in the treatment of liver diseases, such as chronic viral hepatitis, chemical or drug induced hepatic damage.
  • Its early confirmed efficacy is to normalize elevated blood alanine aminotransferase (ALT) from different etiologies, however, it can rarely affect the rest hepatic enzymes.
  • In addition, the lowering or normalization of ALT in most cases occurs during DDB treatment, withdrawal of DDB administration results in ALT re-elevated.
  • Hence, for a long time, it has been only used as adjuvant of liver disease therapy.
  • It is still controversial that whether DDB can be beneficial to liver histology.
  • The normalization of ALT in hepatitis does not indicate therapeutic efficacy if without substantial liver histology improvement.
  • In recent years, more studies showed that DDB might have new therapeutical potentials in liver diseases, it may have the effect of anti-viral, anti-malignancy.
  • These new findings were mostly based on the in vitro or animal experiments, more basic studies and clinical trials are needed to ascertain these efficacies, prior to that stage, it is recommended to be cautious to apply DDB clinically for anti-virus and anti-malignancy purposes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994699.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; adjuvant / dimethyl diphenyl bicarboxylate / liver disease / schisandra chinensis / schisandrin B / viral hepatitis
  •  go-up   go-down


3. Zhang CF, Zhang CQ, Zhu YH, Wang J, Xu HW, Ren WH: Ginkgo Biloba Extract EGb 761 Alleviates Hepatic Fibrosis and Sinusoidal Microcirculation Disturbance in Patients with Chronic Hepatitis B. Gastroenterology Res; 2008 Dec;1(1):20-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ginkgo Biloba Extract EGb 761 Alleviates Hepatic Fibrosis and Sinusoidal Microcirculation Disturbance in Patients with Chronic Hepatitis B.
  • BACKGROUND: Few clinical data are available regarding the effect of Ginkgo biloba extract (EGb 761) on liver microcirculation and fibrosis.
  • This randomized, controlled trial is to investigate the effect of Ginko biloba extract EGb 761 on liver fibrosis and hepatic microcirculation in patients with chronic hepatitis B.
  • METHODS: Sixty-four patients with chronic hepatitis B were randomized for intention-to-treat.
  • Thirty-two patients were assigned to treated group receiving EGb 761 plus polyunsaturated phosphatidylcholine (Essentiale), 32 patients received Essentiale as controls.
  • Blood samples were taken for measurement of transforming growth factor beta-1 (TGF-β1), platelet activate factor (PAF), endothelin 1 (ET-1).
  • Twenty-six patients in treated group and 21 patients in control group underwent liver biopsies for histology before and after treatment.
  • Ultrastructural study for sinusoidal microcirculation before and after treatment was carried out on 10 randomly selected patients in each group.
  • RESULTS: In the treated group, after EGb 761 treatment, there was a significant reduction of blood TGF- β1, PAF and ET-1 (p<0.05), whereas this was not observed in the controls.
  • After treatment in both groups, there were significant decrease of ALT, TBil and PT (p<0.05), and significant increase of ALB (p<0.05).
  • Hepatic inflammation and fibrosis significantly alleviated in the treated group, but not in the controls.
  • After EGb 761 treatment, electron microscopy showed red blood cell aggregates and microthrombosis disappeared or decreased in sinusoids; collagen deposits in sinusoidal lumen and Disse space reduced; sinusoidal capillarization alleviated.
  • CONCLUSIONS: EGb 761 can improve sinusoidal microcirculation, alleviate inflammation and inhibit fibrosis through multiple mechanisms, it is effective in the treatment of chronic liver diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994702.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Chronic Hepatitis B / EGb 761 / Endothelin-1 / Ginko biloba / Hepatic fibrosis / Hepatic microcirculation
  •  go-up   go-down


Advertisement
4. Mielczarek M, Chrzanowska A, Scibior D, Skwarek A, Ashamiss F, Lewandowska K, Baranczyk-Kuzma A: Arginase as a useful factor for the diagnosis of colorectal cancer liver metastases. Int J Biol Markers; 2006 Jan - Mar;21(1):40-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The studies were conducted on blood serum from 85 patients with CRCLM obtained one to two days before tumor resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207092.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Skipworth RJ, Smith GH, Stewart KJ, Anderson DN: The tip of the iceberg: a giant pelvic atypical lipoma presenting as a sciatic hernia. World J Surg Oncol; 2006;4:33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tip of the iceberg: a giant pelvic atypical lipoma presenting as a sciatic hernia.
  • BACKGROUND: This case report highlights two unusual surgical phenomena: lipoma-like well-differentiated liposarcomas and sciatic hernias.
  • CASE PRESENTATION: A 36 year old woman presented with an expanding, yet reducible, right gluteal mass, indicative of a sciatic hernia.
  • The tumour was surgically removed through an abdomino-perineal approach.
  • Subsequent pathological examination revealed an atypical lipomatous tumour (synonym: lipoma-like well-differentiated liposarcoma).
  • CONCLUSION: The presence of a gluteal mass should always suggest the possibility of a sciatic hernia.
  • However, in this case, the hernia consisted of an atypical lipoma spanning the greater sciatic foramen.
  • Although lipoma-like well-differentiated liposarcomas have only a low potential for recurrence, the variable nature of fatty tumours demands that patients require regular clinical and radiological review.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Monogr Pathol. 1996;38:207-39 [8744279.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1051-8 [1471725.001]
  • [Cites] Surg Today. 1995;25(12):1066-8 [8645944.001]
  • [Cites] J Urol. 1993 Oct;150(4):1232-4 [8371401.001]
  • [Cites] Br J Surg. 1994 Mar;81(3):447 [8173927.001]
  • [Cites] AJR Am J Roentgenol. 1983 Sep;141(3):579-80 [6603774.001]
  • [Cites] Int Surg. 1970 Aug;54(2):135-41 [5428878.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Apr;17(4):332-4 [2040745.001]
  • [Cites] Gastrointest Radiol. 1991 Spring;16(2):120-2 [2016022.001]
  • [Cites] Spine (Phila Pa 1976). 1998 Oct 1;23(19):2134-6 [9794060.001]
  • [Cites] Obstet Gynecol. 1998 Jun;91(6):998-1001 [9611012.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):258-62 [11757865.001]
  • [Cites] Skeletal Radiol. 1997 Mar;26(3):150-4 [9108224.001]
  • [Cites] Radiology. 2002 Jul;224(1):99-104 [12091667.001]
  • [Cites] Am J Surg. 1964 Jun;107:883-4 [14169023.001]
  • [Cites] Br J Radiol. 2002 Apr;75(892):381-3 [12000699.001]
  • (PMID = 16790047.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1526433
  •  go-up   go-down


6. Yukawa H, Noguchi H, Oishi K, Takagi S, Hamaguchi M, Hamajima N, Hayashi S: Cell Transplantation of Adipose Tissue-Derived Stem Cells in Combination with Heparin Attenuated Acute Liver Failure in Mice. Cell Transplant; 2009 May/Jun;18(5-6):611-618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell Transplantation of Adipose Tissue-Derived Stem Cells in Combination with Heparin Attenuated Acute Liver Failure in Mice.
  • The effect of adipose tissue-derived stem cells (ASCs) in combination with heparin transplantation on acute liver failure mice with carbon tetrachloride (CCl<sub>4</sub>) injection was investigated.
  • CCl<sub>4</sub> is a well-known hepatotoxin and induces hepatic necrosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880629.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acute liver failure / Adipose tissue-derived stem cells (ASCs) / Cell transplantation / Heparin
  •  go-up   go-down


7. O'Neill JK, Stone CA, Sarsfield P, Smith M, Smithson SF, Silver D, Devaraj VS: An association of multiple well differentiated liposarcomas, lipomatous tissue and hereditary retinoblastoma. Sarcoma; 2005;9(3-4):151-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An association of multiple well differentiated liposarcomas, lipomatous tissue and hereditary retinoblastoma.
  • Well differentiated liposarcoma (atypical lipomatous tumour) is a low grade tumour, with no metastatic potential unless dedifferentiation supervenes.
  • When superficial, it recurs locally only occasionally after marginal excision.
  • We present a patient in whom bilateral childhood retinoblastoma was followed by later development of massive confluent areas of low grade liposarcoma and lipomatous tissue affecting the upper extremities and trunk.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521424.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395631
  •  go-up   go-down


8. Acar GO, Cansiz H, Acioğlu E, Yağiz C, Dervişoğlu S: Atypical lipomatous tumour of the head and neck region with dyspnea and dysphagia: a case report. Eur Arch Otorhinolaryngol; 2007 Aug;264(8):947-50
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumour of the head and neck region with dyspnea and dysphagia: a case report.
  • Liposarcoma is one of the most common soft tissue sarcomas in adults.
  • Atypical lipomatous tumour (ALT) rarely occurs in the head and neck region.
  • In this article, a case of a huge ALT arising from the head and neck region and invading nearly entire left hemi-facial region is presented.
  • Clinical and histopathologic features and therapeutic approaches related to this tumour are discussed reviewing the literature.
  • [MeSH-major] Deglutition Disorders / etiology. Dyspnea / etiology. Head and Neck Neoplasms / complications. Liposarcoma / complications

  • Genetic Alliance. consumer health - Dysphagia.
  • Genetic Alliance. consumer health - Dyspnea.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 1996 Oct;37(4):439-43 [8905056.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1020-31 [12379747.001]
  • [Cites] Cancer. 1979 Jan;43(1):162-8 [367565.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):130, 132-3 [12525210.001]
  • [Cites] Cancer. 1979 Feb;43(2):574-84 [421182.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):733-9 [14975977.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):83-93 [12004355.001]
  • [Cites] Am J Otolaryngol. 2004 Nov-Dec;25(6):432-7 [15547814.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):258-62 [11757865.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1051-8 [8625207.001]
  • (PMID = 17361411.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Doyle AJ, Pang AK, Miller MV, French JG: Magnetic resonance imaging of lipoma and atypical lipomatous tumour/well-differentiated liposarcoma: observer performance using T1-weighted and fluid-sensitive MRI. J Med Imaging Radiat Oncol; 2008 Feb;52(1):44-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of lipoma and atypical lipomatous tumour/well-differentiated liposarcoma: observer performance using T1-weighted and fluid-sensitive MRI.
  • The aim of this study was to evaluate observer performance using T1-weighted spin-echo and fluid-sensitive MRI sequences in distinguishing between lipoma and atypical lipomatous tumour/well-differentiated liposarcoma (ALT/WDL).
  • Magnetic resonance images of 51 patients with benign lipoma and ALT/WDL of the musculoskeletal system were reviewed.
  • There were 33 benign lipomas and 18 ALT/WDL.
  • In distinguishing lipoma from ALT/WDL, observer performance was comparable using T1-weighted and fluid-sensitive MR sequences.
  • [MeSH-major] Lipoma / diagnosis. Liposarcoma / diagnosis. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / statistics & numerical data. Soft Tissue Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373826.001).
  • [ISSN] 1754-9477
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


10. Mentzel T, Toennissen J, Rütten A, Schaller J: Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location. Virchows Arch; 2005 Mar;446(3):300-4
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location.
  • Lipomatous tumours, both benign and malignant, arising on the hands are uncommon.
  • We present a rare atypical lipomatous tumour with spindle cell features (synonym: well-differentiated spindle cell liposarcoma) arising on the left palm of a 54-year-old male patient.
  • The well-circumscribed neoplasm was completely excised, and margins were tumour free.
  • Histologically, the neoplasm showed features closely resembling spindle cell lipoma, being composed of mature adipocytic cells associated with bland, neuroid spindle cells staining positively for CD34.
  • However, focally, atypia of adipocytic and stromal cells as well as scattered lipoblasts were noted, and immunohistochemical stainings showed focal overexpression of MDM 2 and CDK4.
  • Aypical lipomatous tumour with spindle cell features may arise very rarely in palmar location and has to be distinguished from a number of benign and malignant mesenchymal neoplasms.
  • [MeSH-major] Hand / pathology. Liposarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1995;427(4):353-63 [8548119.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1192-9 [11106076.001]
  • [Cites] Am J Dermatopathol. 2000 Dec;22(6):496-502 [11190440.001]
  • [Cites] Cancer. 1975 Nov;36(5):1852-9 [1192370.001]
  • [Cites] Am J Clin Oncol. 2001 Feb;24(1):81-4 [11232956.001]
  • [Cites] Am Surg. 1975 Feb;41(2):117-20 [1122062.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):126-33 [7459800.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):30-41 [9892106.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 2000 Jun;34(2):185-7 [10900638.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):255-66 [11598853.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1182-9 [8827023.001]
  • [Cites] Acta Orthop Belg. 1994;60(3):334-5 [7992615.001]
  • [Cites] J Bone Joint Surg Am. 1994 Sep;76(9):1360-2 [8077265.001]
  • [Cites] Ann Diagn Pathol. 2000 Dec;4(6):354-60 [11149965.001]
  • [Cites] Gan No Rinsho. 1989 Feb;35(3):437-41 [2926990.001]
  • [Cites] J Hand Surg Am. 1989 Jul;14(4):700-4 [2754203.001]
  • [Cites] Ann Diagn Pathol. 2002 Apr;6(2):83-93 [12004355.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):913-21 [8067512.001]
  • [Cites] Ann Plast Surg. 1983 Nov;11(5):431-3 [6651174.001]
  • [Cites] Cutis. 1987 Jul;40(1):29-32 [3665587.001]
  • [Cites] J Bone Joint Surg Am. 1965 Jun;47:727-40 [14299665.001]
  • (PMID = 15719245.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Masood AI, Javed AA, Mateen A, Gurchani SA: Concomitant chemoradiation using gemcitabine in locally advanced hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor response was assessed by computed tomography (CT) eight weeks after completion of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962724.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Widemann BC, Fox E, Adamson PC, Baruchel S, Kim A, Ingle AM, Bender JG, Stempak D, Balis FM, Blaney SM: Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. J Clin Oncol; 2009 May 20;27(15_suppl):10012

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No objective responses were observed, but 2 pts had tumor shrinkage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962524.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Plummer R, Hayward L, Lorigan P, Soriano V, Moiseyenko V, Szyldergemajn S, Prados R, Smyth J, Calvert H: Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). J Clin Oncol; 2009 May 20;27(15_suppl):9059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM).
  • : 9059 Background: AUM remains incurable in most patients (pts).
  • DTIC alone had a 8-15% response rate (RR), while plitidepsin (Aplidin [APL]) showed a 6% RR and a 14% stable disease (SD) in a Phase (Ph) II study in 35 relapsed/refractory pts after DTIC failure.
  • Furthermore, APL + DTIC has additive activity in preclinical models.
  • METHODS: This multicenter Ph Ib study aim to determine the safe recommended dose (RD) of APL on days 1, 8 & 15 + DTIC only day 1 q4wk.
  • RD was defined as the highest dose with >5 days G4 neutropenia or G4 thrombocytopenia (TC) and/or febrile neutropenia (FN); any drug-related ≥ G3 toxicity (except nausea/vomiting or hypersensitivity reaction) in cycle 1.
  • RESULTS: Of 28pts with AUM, 23 were evaluable for DLT; 57% were males, median (med) age was 48 y (20-77), med ECOG 0 (0-2) and med LDH was 226 IU/l (126-983).
  • Most pts (96%) had metastasis with a median of 2 sites involved (1-5).
  • Dose levels of APL + DICT (mg/m<sup>2</sup>), were: DL1 (1.8 + 800), 7 pts; DL2 (2.4 + 800), 8 pts; DL 2b (2.4 + 1000), 5 pts; DL3 (3.0 + 800), 8 pts.
  • Pts received 4 (2-6), 2 (2-5), 2 (1-2), 2 (1-8) median cycles respectively.
  • The number of DLTs were 1/6, 1/7, 2/4, 2/6, respectively.
  • DLTs were G3 ALT in 4 pts and FN + TC in 1 pt.
  • The MTD was at DL 2B and the RD was at DL 2.
  • There were 3 partial responses (PR, 14%) and 4 SD > 3 months (19%); all PR at DL2/3.
  • Five pts were not evaluable, 2 pts had G3 hypersensitivity reactions related to Cremophor oil (APL formulation) and 1 pt had a idiosyncratic reaction to DTIC with prolonged pancytopenia.
  • One pt had a wrong diagnosis and 1 pt had early progressive disease (PD).
  • CONCLUSIONS: APL + DTIC can be safely combined at ≥ 70% of their respective single- agent RD in AUM.
  • Main DLTs were asymptomatic, transient and reversible ALT elevations.
  • Ph Ib showed 14 % PR and 19% clinically meaningful SD.
  • A randomised Ph II study of DTIC + APL vs APL alone is ongoing.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962154.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. De Groot JF, Prados M, Urquhart T, Robertson S, Yaron Y, Sorensen AG, Norton A, Batchelor T, Drappatz J, Wen P: A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol; 2009 May 20;27(15_suppl):2047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At least 1 post-baseline tumor assessment at 4 weeks was available for 26 pts.
  • Based on investigator assessment of bidimensional contrast-enhancing tumor measurements, 10 pts (38%) had a best radiologic response of >= 50% reduction from baseline (including 1 pt with a 100% reduction), 9 pts (35%) had tumor measurement changes ranging from +24% and -49%, and 7 pts (27%) had a >= 25% increase in tumor burden.
  • Of the 17 anti-angiogenic-naïve pts, 9 (53%) had a best radiologic response of >= 50% reduction in tumor burden.
  • CONCLUSIONS: XL184 at a dose of 175 mg PO qd, has demonstrated substantial activity in pts with progressive or recurrent GBM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964644.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Nakagawa K, Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Kiriyama T: Phase I study of sunitinib (SU) in combination with pemetrexed (Pem) in patients (pts) with advanced solid tumors (ST). J Clin Oncol; 2009 May 20;27(15_suppl):e14630

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A standard "3+3" design was employed in both treatment schedules and treatment continued until tumor progression or dose-limiting toxicity (DLT) was observed.
  • One pt with NSCLC had a documented PR with cavity formation inside the tumor.
  • CONCLUSIONS: SU 37.5 mg/day (CDD schedule) plus Pem 500mg/m<sup>2</sup> every 21 days, and SU 50 mg/day (S-2/1 schedule) plus Pem 500mg/m<sup>2</sup> every 21 days were well tolerated and associated with encouraging antitumor activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964182.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, Oliveri F, Filipponi F, Bartolozzi C, Del Tacca M, Ricci S: A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary data. J Clin Oncol; 2009 May 20;27(15_suppl):4592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour response was assessed according to RECIST criteria every 9 weeks.
  • The S+5FU association is feasible, well tolerated and AEs were predictable and manageable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963116.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Lee P, Al-Adhami M, Ryan J: Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).
  • Pts with ≥ 25% tumor shrinkage continued treatment with AV-951, while pts with < 25% change from baseline were randomly assigned to receive AV-951 or placebo for 12 wks (double-blinded).
  • The AE profile of AV-951 is consistent with that of a selective VEGFR inhibitor, with minimal off-target toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: SCH 66336 in combination with TMZ is well-tolerated and shows promising response when administered to patient when stable on TMZ alone or after RT and TMZ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Drullinsky P, Fornier MN, Sugarman S, D'Andrea G, Troso-Sandoval T, Seidman AD, Yuan J, Patil S, Norton L, Hudis C: Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer.
  • : 590 Background: CMF (C 600 mg/m<sup>2</sup>, M 40 mg/m<sup>2</sup>, F 600 mg/m<sup>2</sup>) is an option for adjuvant therapy for patients with low risk early stage breast cancer.
  • DD regimens as predicted by mathematical models of cancer growth and treatment response are superior.
  • We previously demonstrated the safety of DD EC (epirubicin/cyclophosphamide) followed by paclitaxel at 10-11 day (d) intervals.
  • We investigated the feasibility of administering DD adjuvant CMF every 14 d and then every 10-11 d in a 2-stage phase II trial.
  • METHODS: An initial cohort (A) was treated q 14 d with PEG-filgrastim (Neulasta) support.
  • A second cohort (B) was treated every 10-11 d with filgrastim/Neupogen x 5 d and then, based on feasibility, modified (cohort C) to use 7 d filgrastim.
  • The primary end point was feasibility defined as having ANC > 1.5 x 10<sup>3</sup>/uL on day 1 of planned treatment for all 8 cycles with no grade 3 or higher non-hematologic toxicity.
  • All three cohorts were tested using a Simon's two-stage optimal design with type I and type II errors set at 10%.
  • This design would effectively discriminate between true tolerability (as protocol-defined) rates of< 60% and> 80%.
  • Cohort A: 38 pts with early stage breast cancer were accrued from 3/2008 though 6/2008.
  • Cohort B: 7 pts were accrued from June 2008 through August 2008.
  • Cohort C: Is still open with 16 pts accrued from August 2008 through December 5, 2008.
  • RESULTS: Median age 51: range 38 to 78.
  • Cohort A: 29/38 pts completed 8 cycles of CMF.
  • The regimen was considered feasible.
  • 2 other pts completed 7 cycles and were withdrawn for depression and grade 2 transaminitis.
  • The 7 other pts completed between 1 and 6 cycles of CMF were withdrawn as follows: 3 personal, 1 (grade 3) bone pain, 2 allergy unrelated to CMF, and 1 seizure.
  • Cohort B: 7 pts were accrued.
  • 6 out of 7 pts could not complete 8 cycles of chemotherapy secondary to neutropenia and 1 secondary to grade 3 ALT elevation.
  • Cohort C: Accrual has not been completed.
  • 16 pts are currently enrolled.
  • CONCLUSIONS: Dose dense adjuvant CMF is feasible at 14 d intervals with PEG-filgrastim support.
  • Adjuvant CMF every 10-11 days with filgrastim given for 5 days beginning day 2 is not feasible.
  • Accrual is ongoing for CMF at 10-11 days with filgrastim x 7 days.
  • Updated results will be available for Cohort C.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Frentzas SN, Groves MD, Barriuso J, Harris D, Reardon D, Curtis MC, Suttle AB, Ma B, Lager JJ, de Bono JS: Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):2040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964651.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence TS, Abrams R, Leslie W, Zalupski M: Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility included tissue diagnosis of adenocarcinoma, unresectable by radiological criteria, Zubrod performance of 0-2, ANC of ≥ 1500/mm3, platelets ≥ 100,000/mm3, creatinine < 2 mg/dl, bilirubin < 3 mg/dl, ALT and AST ≤ 2.5 x ULN, and informed consent.
  • CONCLUSIONS: High dose radiotherapy and concurrent FDR-G, utilizing the techniques above, is well tolerated and results in highly encouraging response rates, local control rates and overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14527 Background: Preclinical studies demonstrate synergistic anti-tumor activity with the combination of E + C.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Saleh MN, Pitot H, Maleski J, Leopold L, Forero A: Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers.
  • : e14537 Background: Over-expression of Bcl-2 family proteins is common in human cancers.
  • Initial trials of the oral, pan-Bcl-2 inhibitor AT-101 showed acute dose limiting toxicity of Gr 3-4 AST/ALT (MTD 40 mg/d) and ileus with prolonged dosing daily (QD) for 21/28 days per cycle (Saleh, NCI/EORTC, 2005; James, ASCO, 2006 and Saleh, ASCO, 2007).
  • MTD in the QD schedule has been previously reported.
  • In this study different dosing schedules of AT-101 were tested in adults with advanced cancers and final results for the pulse dosing schedule of twice a day for three days every other week (b.i.d. x 3d EOW) are being reported.
  • METHODS: Serial patient (pt) cohorts received AT-101 at escalating doses of 30-80 mg b.i.d. x 3d EOW.
  • Adverse events (AEs) were graded by the NCI CTCAE v3.0.
  • Efficacy was determined by RECIST.
  • RESULTS: 37 pts have been enrolled.
  • Safety data is available on 34/37 pts.
  • In this b.i.d. x 3d EOW dosing schedule, ileus/small bowel obstruction (SBO) occurred in 3 pts (one at each dose level of 30, 40 and 50 mg) and was the dose limiting toxicity for this schedule.
  • Of note, the SBO that occurred at 30 mg was felt to be unrelated to study agent therefore, 30 mg b.i.d. x 3d EOW was the MTD determined for this schedule.
  • The most common (>50%) grade 1-2 AEs included: nausea, vomiting, diarrhea, fatigue and anorexia.
  • Grade 3-4 AEs occurring in > 2 pts include: nausea, abdominal pain, elevated AST (3 pts each), vomiting, fatigue, dehydration (4 pts each), hypokalemia (5 pts).
  • Stable disease was reported in 13/37 (35%) pts.
  • One pt with NSCLC continues on study with stable disease for 33 cycles and 2 additional pts were on study with stable disease for 18 and 9 cycles.
  • The mean Plasma C<sub>max</sub> was 301 ng/ml (+ 477 ng/ml SD) and mean AUC for 30 mg b.i.d.x3d EOW was 1080 ng*hr/ml (+ 1990 ng/ml SD) with a median peak concentration at 4 hours post dose.
  • CONCLUSIONS: Pulse dosing of AT-101 achieved an MTD of 30mg b.i.d. x 3d EOW and is associated with reduced toxicity than continuous daily dosing, and may be preferable in combination regimens.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K: A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503. J Clin Oncol; 2009 May 20;27(15_suppl):7561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503.
  • : 7561 Background: Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC.
  • However, the optimum chemotherapy regimen has not been determined.
  • TORG 0503 was conducted to evaluate platinum-based third generation regimens in this clinical setting.
  • METHODS: Patients with completely resected stage IB, IIA, IIB or stage IIIA NSCLC were stratified by stage (IB/IIA vs. IIB/IIIA) and institution and randomized to receive 3 cycles of DOC (60 mg/m2, day 1) plus CIS (80 mg/m2, day 1) or 3 cycles of PAC (200 mg/m2, day 1) plus CAR (AUC 6, day 1).
  • Both regimens were repeated every 3 - 4 weeks.
  • Other eligibility criteria included ECOG PS 0-1, age ≥20, and =<70 years old, adequate organ function, no prior chemotherapy or radiotherapy.
  • Patients who underwent pneumonectomy were excluded.
  • The primary endpoint was 2-year relapse free survival (RFS), and secondary endpoints were overall survival (OS), quality of life (QOL), feasibility and toxicity.
  • RESULTS: 111 patients were randomized between April 2006 and July 2008, 58 patients to DOC+CIS (DC) and 53 to PAC+CAR (PA).
  • Patients' demographics (DC/PA): median age 63/59 years, 60%/66% male, 17%/22% PS 1, 79%/73% adenocarcinoma, 40%/40% of patients were stage IB/IIA, 60%/60% IIB/IIIA.
  • Feasibility: 93% (54/58) of patients allocated to DC and 92% (49/53) patients in the PA arm completed 3 planned cycles of chemotherapy.
  • Toxicities: DC vs.
  • PA: Grade (G) 3/4 neutropenia (86%/75%), G3/4 anemia (2%/0%).
  • G 3 febrile neutropenia (10%/4%), G2 ALT (0%/10%), G2 creatinine (17%/0%), G2-4 allergy (0%/4%), G2 alopecia (43%/47%), G2/3 fatigue (5%/10%), G2/3 anorexia (43%/22%), G2/3 nausea (47%/22%), G2/3 vomiting (31%/12%), G2 diarrhea (12%/8%), G2 constipation (2%/4%), G2/3 sensory neuropathy (3%/33%), G2/3 arthralgia (0%/31%), G2 myalgia (2%/8%).
  • No treatment related deaths were observed in either arm.
  • CONCLUSIONS: Both docetaxel plus cisplatin and paclitaxel plus carboplatin are safe and feasible regimens as adjuvant chemotherapy.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Okusaka T, Kasugai H, Ishii H, SM-11355 Japan Study Group: A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with unresectable HCC were randomized 2:1 to receive an injection of SM-11355 or zinostatin stimalamer suspended in lipiodol into the hepatic artery at doses of up to 6 mL (SM-11355: 120 mg; zinostatin stimalamer: 6 mg) according to the tumor size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963097.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Chen L, Shiah HS, Chen CY, Lin YJ, Lin PW, Su WC, Chang JY: Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up-regulation of mTOR expression has been noted in 40-45% of HCC, and preclinical studies suggest mTOR inhibitor can effectively inhibit proliferation of HCC cells as well as growth of HCC xenograft in mice.
  • RESULTS: A total of 36 pts (M/F 34/2; median age 58.5, range 28-75; Child-Pugh's class of A/B 31/5) were enrolled.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963093.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Muzikansky A, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Sahani DV: Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J Clin Oncol; 2009 May 20;27(15_suppl):4578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increase in adjusted post- to pre-treatment SUV increased the risk for tumor progression (hazard ratio=3.054).
  • FDG-PET showed significant early decreases in SUVmax following treatment, and these changes correlated with tumor response and time to tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963071.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were evaluable for safety and survival and twenty seven patients (79.4%) were evaluable for tumor response.
  • CONCLUSIONS: This results showed that the combination chemotherapy with irinotecan, 5-FU and leucovorin was well tolerated and active in taxane and cisplatin refractory patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Tiersten A, Sill M, Muggia F, Elera C, Garcia A, Fracasso P, Swensen R, Warshal D, Mannel R, Gynecologic Oncology Group: Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol; 2009 May 20;27(15_suppl):5544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study.
  • : 5544 Background: Dose-dense regimens improve outcome for women with breast cancer.
  • We investigated the feasibility of dose-dense CP for women with ovarian cancer.
  • METHODS: Pts with untreated stage III/IV ovarian cancer received C AUC 5 and P 175 mg/m2 day 1, pegfilgrastim 6 mg day 2 every 2 weeks for 6 cycles.
  • Dose-limiting toxicity (DLT) was defined as: febrile neutropenia, grade 4 neutropenia ≥7 days, grade 4 thrombocytopenia (tcp), grade 3 tcp with bleeding, dose delay >2 weeks, grade 3/4 non-hematologic toxicity (excluding fatigue, hypersensitivity, nausea/vomiting, alopecia, constipation, diarrhea or bone pain), and any treatment related death.
  • The study utilized a 2-stage sequential design (20 pts/stage) with DLTs in 6 cycles determining regimen feasibility.
  • RESULTS: Between September 2006 and September 2008, 43 pts enrolled.
  • Twenty and 17 patients were evaluable for toxicity over 6 cycles in stages 1 and 2 respectively.
  • Six DLT's were observed for both stages.
  • Thirty pts completed treatment and 12 did not [DLTs (6), paclitaxel hypersensitivity reactions (2), progression (1), patient choice (1), infection (1) and death unrelated to treatment (1)].
  • One pt remains on treatment.
  • The 6 DLTs resulting in treatment discontinuation included grade 3 neuropathy (2), grade 4 neuropathy (1), grade 4 tcp (1), grade 4 tcp/grade 3 febrile neutropenia (1), and grade 4 SVT (1).
  • Six other DLTs not preventing treatment completion included grade 3 infection (1), grade 3 AST/ALT elevation (1), grade 3 confusion (1), grade 3 dehydration (1), grade 3 neuropathy (1) and grade 4 tcp (1).
  • Other toxicities resulting in treatment delays included grade 3 tcp (1), grade 3 fatigue (1) and grade 2 neuropathy (2).
  • There were 5 P dose reductions and 4 C dose reductions.
  • CONCLUSIONS: Seventy-two percent pts completed 6 cycles of dose-dense CP.
  • Based on DLTs (at least 12 in 37 evaluable pts), this regimen is not feasible.
  • Given the neuropathy and tcp, we do not recommend further investigation in a phase III trial.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L: Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):e15543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following our dose-finding phase I study, the present phase II neo-adjuvant (NA) EC trial was designed to examine the pCR rate using C, OXP and RT, with secondary end-points of evaluating toxicity, quality of life, and GEP of tumor tissue for correlation to therapeutic response.
  • GEP using Agilent microarrays was conducted on primary tumor tissue pre-treatment (Rx), day (D) 17 and at E; > 50% viable tumor cells were required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Uronis HE, Bullock K, Blobe G, Hsu S, Morse M, Nixon A, Haley S, O'Neill M, Hurwitz H, Bendell J: A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors.
  • : e15506 Background: Dasatinib (D) is a small molecule tyrosine kinase inhibitor with activity against both bcr-abl and src.
  • Cetuximab (C) is a monoclonal antibody that blocks EGFR.
  • Preclinical models suggest D reverses resistance to G.
  • In addition, src and EGFR pathways interact; synergism of dual blockade by D + C is possible.
  • We evaluated two combination regimens, GD and GDC, in a Phase I dose escalation study.
  • METHODS: Patients (pts) with advanced solid tumors were enrolled in cohorts of 3-6 to either GD or GDC.
  • G was dosed in mg/m<sup>2</sup> weekly for 3 of 4 weeks, D was dosed in mg PO BID, and C was dosed at 250 mg/m<sup>2</sup> weekly after loading dose of C=400; cycle length was 28 days.
  • Dose levels were as follows:.
  • 1) G 1000 + D 50 ± C;.
  • 2) G 1,000 + D 70 ± C;.
  • 3) G 1,000 + D 100 ± C.
  • Standard cycle 1 DLT definitions were used.
  • Eligible pts had advanced solid tumors, adequate organ and marrow function, and no co-morbidities that would increase risk of toxicity.
  • Serum, plasma, and skin biopsy biomarkers were obtained pre- and on treatment.
  • RESULTS: 25 pts have been enrolled, including 21 with pancreatic adenocarcinoma, 3 of whom had received prior G. 21 pts were evaluable for toxicity and 18 for efficacy.
  • Four DLT were observed: Gr 3 ANC with infection (GDC1, n=1), Gr 3 ALT (GD2, n=2), and Gr 5 pneumonitis (GDC2, n=1).
  • Possible treatment-related adverse events in later cycles included: Gr3-4 ANC (n=4), Gr4 colitis (n=1), Gr3 bilirubin (n=2), Gr3 Hgb (n=2), Gr3 Plt (n=2), Gr3 edema/fluid retention syndrome (n=1), and Gr3 vomiting (n=2).
  • One previously untreated pt had a partial response.
  • Eight of 18 pts, 3 of whom had received prior G, had stable disease as best response, median duration = 5 months (range 1-7).
  • Biomarker results are pending.
  • CONCLUSIONS: The MTD of the GD arm is G1000/D50BID.
  • Stable disease in previous G-refractory pts was noted.
  • Hematologic toxicities were dose-limiting; later toxicities including hematologic, LFT changes, pneumonitis, and fluid retention were seen.
  • To address these toxicities, once daily dosing of D will be explored, followed by an expanded cohort of G + daily D vs G + bid D in pts with treatment-naïve pancreatic cancer.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Saltz L, Infante J, Schwartzberg L, Stephenson J, Rocha-Lima C, Galimi F, Dillingham K, Hsu M, Wiezorek J, Fuchs C: Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol; 2009 May 20;27(15_suppl):4079

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AMG 655 activates caspases and induces apoptosis in sensitive tumor cells.
  • Best overall tumor response: 5 partial responses (2 unconfirmed, both underwent resection); 6 stable disease; 1 pt had non-measurable disease at baseline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961630.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Cioffi A, LeCesne A, Blay J, Delaloge S, Yovine A, Maki R, Nieto A, Jiao JJ, Demetri GD: Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its unique antitumor properties, attributed to specific binding to the small groove of DNA, have been demonstrated activity against soft-tissue sarcoma (STS), ovarian, breast and prostate cancer.
  • CONCLUSIONS: Single-agent trabectedin was reasonably well tolerated, with low rates of drug-related discontinuations and deaths.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ninan JA, Bailey H, Kolesar J, Marnocha R, Eickhoff J, Wright J, Espinoza-Delgado I, Alberti D, Wilding G, Schelman W: A phase I study of vorinostat in combination with bortezomib in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2531 Background: Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an oral histone deacytlase (HDAC) inhibitor that has anti-tumor activity in hematologic malignancies and advanced solid tumors.
  • The treatment plan initially consisted of vorinostat given orally twice daily on days 1-14 with bortezomib IV on days 1, 4, 8, and 11 of a 21 day cycle.
  • Tumor types include: Prostate (1), Colorectal (3), Pancreatic (6), Sarcoma (7), Biliary (1), Thymus (1), GIST (2), Mesothelioma (1), ovarian (1), Neuroendocrine (1), Lung (1), Head and Neck (1), Breast (2), and Cervical (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961857.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Hawkins RE, Hong SJ, Ulys A, Rolski J, Hong B, Sternberg C: An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC).
  • : 5110 Background: The efficacy and safety of pazopanib (paz), a multikinase angiogenesis inhibitor, was evaluated in a randomized, double-blind placebo-controlled phase III study (VEG105192), in treatment-naïve and cytokine-pretreated patients (pts) with advanced RCC.
  • Pts with progressive disease (PD) on placebo had the option to receive paz 800 mg QD via an extension study (VEG107769).
  • METHODS: Pts with ECOG PS ≤ 2, adequate organ function and no other systemic anticancer treatment since PD on VEG105192 were eligible.
  • The primary endpoint was safety.
  • Secondary endpoints included response rate (RR) per RECIST and progression-free survival (PFS).
  • RR was described along with 95% confidence intervals (CIs).
  • PFS was summarized descriptively using Kaplan-Meier estimates for the median, quartiles and PFS rates at 6, 12, and 18 mo along with approximate 95% CIs.
  • RESULTS: 70 placebo pts were enrolled (+ 1 paz pt as an exemption due to symptom improvement).
  • 34 pts (48%) were treatment-naïve and 37 (52%) were cytokine pretreated (at baseline in VEG105192).
  • Median age was 59 y (25-80); baseline ECOG PS 0 (32%), 1 (52%), and 2 (14%).
  • Median time from randomization to placebo in VEG105192 to start of paz treatment on VEG107769 was 6.4 mo (1-18 mo).
  • At VEG107769 clinical cut-off (May 08), 21 (30%) pts had died, 40 (56%) pts had discontinued paz, and 31 (44%) pts were still on paz.
  • Median exposure to paz was 5.7 mo.
  • Most pts died or discontinued paz due to PD.
  • The majority of adverse events (AEs) were Gr 1/2.
  • Gr 3/4 AEs were experienced by 21%/7% of pts.
  • The most common AEs were hypertension (46%; 4% Gr 3/4), hair color changes (39%; 0% Gr 3/4), diarrhea (38%; 1% Gr 3/4), anorexia (24%; 1% Gr 3/4), and nausea (24%; 0% Gr 3/4).
  • Two pts had fatal AEs: sudden death and gastrointestinal hemorrhage.
  • The most common Gr 3 chemistry laboratory abnormalities were hyponatremia (7%) and elevated ALT (7%) and AST (6%); no Gr 4.
  • RR was 32.4% (95% CI: 21.5, 43.3); median PFS was 8.3 mo (95% CI: 6.1, 11.4 mo).
  • CONCLUSIONS: Patients with advanced RCC who developed PD on placebo in a phase III study subsequently achieved clinical benefit from paz treatment in this extension study.
  • These findings support the continued evaluation of paz in advanced RCC.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Yau CC, Chen PJ, Curtis CM, Murphy PS, Suttle AB, Arumugham T, Hodge JP, Dar MM, Poon R: A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):3561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HCC is a highly vascular tumor with increased levels of angiogenic factors including VEGF and VEGFR.
  • DCE- MRI was performed to assess changes in tumor permeability.
  • Median % change in tumor permeability (K<sup>trans</sup>) following 3 weeks of pazopanib administration at the MTD (5 pts) was 45%.
  • Changes in tumor DCE-MRI parameters were seen following repeated dose pazopanib administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Conley AP, Araujo D, Ludwig J, Ravi V, Samuels BL, Choi H, Thall PF, Patel S, Benjamin R, Trent J: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Chan SL, Mo FK, Koh J, Hui EP, Yu SC, Lai PB, Chan HL, Chan VT, Chan AT, Yeo W, Mok T: Predictors of treatment outcomes in early stage hepatocellular carcinoma (HCC) detected in a surveillance program. J Clin Oncol; 2009 May 20;27(15_suppl):4584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4584 Background: Surveillance for HCC in hepatitis B virus (HBV) carriers aims to improve survival by detection of early resectable tumor.
  • Fifty seven pts (54.3%) had solitary tumor but only 34 (32.4%) are amenable to resection.
  • Absence of cirrhosis (p=0.0072) and normal albumin level (p=0.0379) are predictors of surgical resection while tumor size and number are not.
  • Liver function is more important than tumor characteristics in determining the outcome of HCC detected in the surveillance program.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963096.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Elser C, Hirte H, Kaizer L, Mackay H, Bindra S, Tinker L, MacAlpine K, Wang L, Sidor C, Oza A: Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was tumor response by RECIST or CA-125.
  • CONCLUSIONS: MKC-1 was well tolerated in both patient populations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962602.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Hanna NH, Estes D, Arnott J, Marcotte S, Hannah A, Sidor CF, West H, Clamon G, Hoang T: Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 19 phase 2 pts, 18 were evaluable for tumor response.
  • The combination is well tolerated with 17% of patients achieving a confirmed PR thus far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962522.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P: Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5 of the 7 BRAF V600E+ pts treated at ≥ 240 mg BID had tumor regression, up to 83%, with 1 confirmed partial response (PR) and 1 unconfirmed PR (too early); 2 of 4 pts with unknown V600E status had tumor regression, up to 50%, with 1 confirmed PR; 2 BRAF wild-type pts had progressive disease.
  • All 7 pts with tumor regression remain progression-free, ranging from 4 to 14 months.
  • 3 thyroid cancer pts with V600E mutations have tumor regression (range 9-16%) and are progression-free (4-7 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Wilson W, O'Connor OO, Roberts AW, Czuczman M, Brown J, Xiong H, Xiong H, Chiu Y, Krivoshik A, Enschede S, Humerickhouse R: ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J Clin Oncol; 2009 May 20;27(15_suppl):8574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients (pts) were dosed on days 1-14 of a 21 d cycle, 10-440mg (M06-814) or 10-250mg (M06-873).
  • Dose limiting toxicities, 14/21 d dosing, in M06-814 occurred at 160mg (bronchitis), 315mg (elevated ALT and grade 4 TCP) and 440mg (worsening pleural effusion in a pt with underlying afib), and in M06-873 at 110mg (tumor lysis and grade 4 TCP) and 250mg (grade 4 TCP).
  • CONCLUSIONS: ABT-263 showed favorable PK and safety profiles with anti-tumor activity in relapsed/refractory CLL/SLL and follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Traina TA, Theodoulou M, Feigin K, Patil S, Geneus S, Modi S, Fornier M, Lake D, Norton L, Hudis C: Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab. J Clin Oncol; 2009 May 20;27(15_suppl):1131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab.
  • Median (med) age 64 yrs (42-71), med ECOG PS 1 (0-1), ER/PR(+) 3, HER-2(+) 6, sites of MBC: bone (2), viscera (4), soft tissue (5).
  • CONCLUSIONS: Capecitabine (7 - 7) + lapatinib appears well tolerated compared to C(14 - 7)+L (Geyer et al).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Yoshimatsu K, Yokomizo H, Otani T, Osawa G, Ogawa K: Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study regimen is that oral administration of S-1 at 40 mg b.i.d. for 21 consecutive days followed by a 7-day rest period and intravenous infusion of CPT-11 at a dose of 80 mg on days 1 and 15 are performed with weekly subcutaneous injection of peptide vaccine.
  • CONCLUSIONS: Treatment with peptide vaccine and S-1/CPT-11 CT was well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Kang D, Wang E, Wang D, Amantea M, Hsyu P: Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):3048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma.
  • : 3048 Background: Tremelimumab is a fully human monoclonal antibody targeted against CTLA4, a protein on T cells critical for regulating T-cell activities, which is under development for treatment of various cancers, including melanoma.
  • Population PK analysis was conducted using concentration-time data from 450 pts, most with melanoma or solid tumors, enrolled in four phase I or II studies that evaluated PK, tolerability, and efficacy of single-agent tremelimumab.
  • METHODS: Tremelimumab was administered intravenously either as single dose or multiple doses every 4 or 12 weeks; doses varied between 0.01 and 15 mg/kg.
  • PK was determined using nonlinear mixed-effect modeling implemented in NONMEM VI.
  • Baseline characteristics, including body weight, ECOG score, age, sex, serum creatinine, AST, ALT, and bilirubin, and formulation effects were investigated as potential factors affecting PK.
  • Tremelimumab plasma concentrations were determined using a sensitive, specific, validated ELISA assay.
  • RESULTS: A two-compartment linear model adequately described tremelimumab concentration-time data; an additive residual error model was employed on log-transformed data.
  • Initial and terminal half-lives were 2.5 days and 22 days, respectively.
  • Estimated parameter values were: 0.0109 L/hr for CL (clearance), 3.72 L for V1 (central volume of distribution), 0.0172 L/hr for Q (intercompartment clearance), and 3.31 L for V2 (peripheral volume of distribution).
  • Females had 29.6% smaller V2 compared with males.
  • Both CL and central V1 increased with weight.
  • An ECOG score of ≥1 showed 20.2% increase in CL compared with a score of 0.
  • New commercial formulation decreased CL by 18.5%.
  • The model-predicted area under concentration-time curve value in females was 13.3% greater than males (p=0.5).
  • None of the other covariates tested significantly affected PK.
  • Furthermore, tremelimumab was tolerated in most pts at all doses tested.
  • CONCLUSIONS: PK of tremelimumab were shown to be affected by weight, baseline ECOG score, and formulation.
  • However, no effects other than weight were considered clinically significant enough to warrant treatment regimen change.
  • Further investigation of PK-response relationships is warranted.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Dennis PA, Blumenthal G, Ballas M, Gardner E, Kawabata S, LoPiccolo J, Helsabeck C, Root H, Figg WD, Bernstein W: A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PBMCs as well as optional tumor biopsies were collected for Akt inhibition and expression of markers of ER stress (ERS).
  • Tumor types included NSCLC (3), SCLC (2), thyroid (3), pancreatic (1), colorectal (1), and renal cell (1).
  • CONCLUSIONS: N appears to be well tolerated in subjects with advanced solid tumors at 2.5 times the FDA approved dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Takahashi T, Yamamoto N, Murakami H, Ohe Y, Kunitoh H, Nokihara H, Koshiji M, Tamura T: A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):2572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2572 Background: Enz is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through PKC and PI-3 kinase/AKT.
  • CONCLUSIONS: Both schedules of Enz in combination with Pem are well tolerated and clinically active in pts with advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Koolen S, Witteveen PO, Garcia-Ribas I, Callies S, Andre V, Kronemeijer RH, Nol A, Beijnen JH, Voest EE, Schellens JH: Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients (pts) with advanced solid tumors.
  • : 2576 Background: LY2334737 (LY) is an orally available valproic acid prodrug of gemcitabine that was developed to overcome the extensive first-pass metabolism of gemcitabine to 2',2'-difluorodeoxyuridine (dFdU).
  • The objectives of this study were to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and pharmacokinetics (PK) of LY as monotherapy and in combination with erlotinib.
  • METHODS: Eligible pts had ECOG PS < 2 and adequate hematologic, renal and hepatic function.
  • In Arm A, LY was given daily for 14 days in a 3-week cycle.
  • Pts assigned to Arm B also received erlotinib daily 100 mg continuously.
  • Dose escalation was based on observed toxicity and the modified continual reassessment method (mCRM).
  • The dose was maximally increased by 100% depending on the toxicity observed in the previous cohort.
  • PK of LY, gemcitabine, dFdU and intracellular metabolites were determined.
  • RESULTS: 33 pts (21 m, 12 f, median age 60 yrs (range 24-81)) were treated at 5 different dose-levels (range 5-50 mg/day).
  • Pts received a median of 3 cycles (range 2-17).
  • Three out of 7 pt treated with 50 mg experienced 5 dose limiting toxicities (DLT).
  • DLTs observed at 40 and 50 mg include fatigue (4 pt), thrombocytopenia (1 pt), GGT elevation (1 pt), AST/ALT elevation (1 pt), fever (1 pt), and pulmonary embolism (1 pt).
  • One death was possibly related to LY intake.
  • This pt, treated with 40 mg LY, developed on day 15 dyspnea, hypovolemic shock, and suddenly died.
  • No grade 3 or 4 toxicities were reported at dose-levels < 40 mg.
  • The most common adverse events were fatigue, vomiting, nausea, pyrexia, anorexia, and diarrhea.
  • Two pts with mesothelioma were stable for > 9 months.
  • One pt with refractory prostate cancer presented a PSA CR as assessed by investigator.
  • The PK show dose-proportional increase in exposure of both LY and gemcitabine.
  • Both LY and gemcitabine are rapidly cleared, thus no accumulation occurs.
  • The metabolite dFdU accumulates due to its long half life.
  • CONCLUSIONS: LY displays linear PK.
  • The dose level of 50-mg is non-tolerable and 40-mg is being confirmed as the MTD as single agent and in combination with 100 mg erlotinib.
  • Antitumor activity warrants further development.
  • Pt accrual is ongoing.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961892.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M: Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: AR-67 was infused over 1 hour for 5 days of a 21-day cycle using an accelerated titration phase I trial design.
  • Tumor types included: colorectal (8), non-small cell lung (NSCLC) (4), small cell lung (3), soft tissue sarcoma, (3), head and neck (2), prostate (2), and other (4).
  • The RP2D is 7.5 mg/m<sup>2</sup>/day for 5 days of a 21-day cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A: Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies.
  • : 3511 Background: Src kinase is central to the proliferation, apoptosis and metastasis of tumor cells.
  • KX2-391 has a much wider spectrum of solid tumor activity in vitro, and is more potent in mouse xenografts, as compared to other multikinase Src/Abl inhibitors.
  • CONCLUSIONS: KX2-391 has a favorable PK profile, is well-tolerated, demonstrates preliminary evidence of biologic activity and should be further evaluated in Phase II trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Kwak EL, Camidge DR, Clark J, Shapiro GI, Maki RG, Ratain MJ, Solomon B, Bang Y, Ou S, Salgia R: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol; 2009 May 20;27(15_suppl):3509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types included colorectal, pancreatic, sarcoma, ALCL and NSCLC.
  • There has been 1 confirmed PR in a sarcoma pt with ALK rearrangement (inflammatory myofibroblastic tumor).
  • Among 10 NSCLC pts whose tumors harbor EML4-ALK rearrangement, 1 pt has had a PR, 2 pts have achieved unconfirmed PR and 4 pts have had SD (3 have experienced reduction in tumor burden by ∼20% in measurable lesions and 1 has been treated for 28 weeks).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961297.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Gomez HL, Philco M, Castaneda C, Pimentel P, Escandon R, Seroogy J, Saikali K, Wolff A, Conlan M: A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence. J Clin Oncol; 2009 May 20;27(15_suppl):1077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Ispinesib appears to be well tolerated on a q14d dosing schedule at doses tested to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Delaloge S, Tedesco KL, Blum J, Gonçalves A, Lubinski J, Efrat N, Osborne C, Lebedinsky C, Tercero JC, Holmes FA: Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):1010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T has EMEA authorization in soft tissue sarcoma after failure of standard treatment.
  • Endpoints were objective response (OR) rate by RECIST, duration of response, progression free survival (PFS), tumor volume changes, safety and exploratory pharmacogenomics (PGx).
  • Tissue samples from 36 pts were collected for RNA expression analysis (XPG + ERCC1 + BRCA1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960738.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Qin S, Yang T, Tak W, Yu S, Tsao C, Kim J, Burock K, Zou J, Voliotis D, Cheng A: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): Asia-Pacific (AP) trial subgroup analyses by baseline transaminase (ALT/AST)/α-fetoprotein (AFP) levels. J Clin Oncol; 2009 May 20;27(15_suppl):4590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatic function influences treatment as a measure of organ damage and tumor stage.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963101.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Yeo W, Goh B, Le Tourneau C, Green SR, Chiao JH, Siu LL: A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a phase I study of 2 weeks of oral administration, clinical antitumor activity was observed in patients with treatment-naive nasopharyngeal carcinoma (NPC) and biological effects consistent with CDK inhibition were detected in tumor biopsy samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Taylor SK, Chia S, Dent S, Clemons M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard K, Leighl N: A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol; 2009 May 20;27(15_suppl):1133

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Pazopanib is well tolerated and demonstrates activity in pretreated breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962243.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Phase 2 Consortium: Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.
  • : 3521 Background: Systemic therapies have had little impact on the outcomes of patients with advanced differentiated thyroid cancers.
  • METHODS: A three-outcome one-stage Phase II trial was conducted to assess the anti-tumor activity and toxicities of the orally bioavailable VEGF/tyrosine kinase inhibitor pazopanib (800 mg daily) in patients with advanced and progressive radioiodine-insensitive differentiated thyroid cancers.
  • Overall, therapy has been well tolerated.
  • CONCLUSIONS: Pazopanib appears to have both a favorable toxicity profile and promising clinical activity in patients with advanced and progressive differentiated thyroid cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S, Novotny W, Durbin B, Weston J, Hurwitz H: Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4129 Background: Preclinical data suggest that recombinant human Apo2 ligand/TNF-related apoptosis-inducing ligand (rhApo2L/TRAIL) induces tumor cell death through pro-apoptotic receptors DR4 and DR5.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961238.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Sawyer MB, Damaraju S, Pituskin E, Damaraju V, Scarfe AG, Bies RB, Hanson J, Clemons M, Kuzma M, Mackey JR: Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression. J Clin Oncol; 2009 May 20;27(15_suppl):2504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression.
  • : 2504 Background: Epirubicin (EPI) is widely used to treat breast cancer.
  • EPI is predominantly metabolized by uridine glucuronosyltransferase (UGT) 2B7 to inactive glucuronides.
  • We previously showed that a UGT enhancer single nucleotide polymorphism (SNP) at position -161 T to C correlated with rates of morphine glucuronidation.
  • METHODS: We performed a prospective pharmacogenetic study of effects of this SNP on EPI metabolism in M0 breast cancer patients (PTS) receiving adjuvant or neoadjuvant FEC100 (5-fluorouracil 500 mg/m<sup>2</sup>, EPI 100 mg/m<sup>2</sup> and cyclophosphamide 500 mg/m<sup>2</sup>) given every 3 wks.
  • PTS with ALT and AST ≤ upper limit of normal (ULN), a total bilirubin ≤ ULN, and normal renal and cardiac function were eligible.
  • EPI levels were drawn at approximately 1 and 24 hrs.
  • Cycle 1 toxicities were assessed using NCIC CTG toxicity criteria.
  • RESULTS: 123 PTS entered this study, mean (range): age 51 (28 - 74), sex 122 F/ 1 M, baseline AST 24 U/L (13-66), ALT 22 U/L (5-90), bilirubin 8 μmol/L (2-26), creatinine 74 μmol/L (50 - 126).
  • PTS were genotyped using Pyrosequencing; 26 PTS were TT homozygotes, 59 were CT heterozygotes, and 33 were CC homozygotes.
  • 5 PTS could not be genotyped.
  • A three compartment population pharmacokinetic model in NONMEM V 1.1 for EPI was used incorporating all PTS.
  • The baseline objective function was 1817, and inclusion of genotype significantly improved the objective function to 1764; CC genotype PTS had decreased EPI clearance 88.9 L/hr compared to CT/TT genotype PTS 129 L/hr, p<0.001.
  • Rates of first cycle grade 3/4 leucopenia were 78% in CC PTS and 48% in CT/TT PTS; consistent with the pharmacokinetic analysis.
  • CONCLUSIONS: A SNP in UGT 2B7 is common and appears to predicts EPI clearance and myelosuppresion in non-metastatic breast cancer PTS and may form the basis for a method to individualize EPI treatment.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Kolevska T, Ryan CJ, Huey V, Weisberg L, Wang S, Baer D, Ghadialy A, Goldstein D, Fireman B, Fehrenbacher L: Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5152

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This regimen was well tolerated, and may be useful in patients who are not suitable candidates for docetaxel based therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964449.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakayama N, Mashiko S, Yamazaki R, Kaneko N, Futagawa S, Nagaoka I: Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level. J Clin Oncol; 2009 May 20;27(15_suppl):e15110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level.
  • : e15110 Background: The alteration of serum-iron level during chemotherapy is already reported (Follezou, NEOPLASMA 1985).
  • However, the correlation to prognosis has not been evaluated.
  • The aim of this study was to evaluate the correlation between prognosis and serum-iron level in advanced / metastatic colorectal cancer (aCRC / mCRC) patients treated by FOLFOX / FOLFIRI.
  • METHODS: Serum-iron levels, hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were analyzed in 58 aCRC / mCRC patients received FOLFOX-4 / FOLFIRI therapy between April 2005 and September 2008.
  • 26 patients received FOLFOX-4 / FOLFIRI therapy as the final chemotherapy died by the time of analysis.
  • These patients were categorized into the high increase group and the low increase group using 200% increase as cut-off value and the prognosis was compared.
  • RESULTS: Mean serum-iron levels in immediately pre and post chemotherapy were 71.7±29.0μg/dl and 186.8±83.2μg/dl, respectively, and significant increase after chemotherapy was observed (p<0.001).
  • This increase was transient and returns to pre chemotherapy level by the start of next course.
  • This alteration was always observed on the chemotherapy.
  • The median survival times from the initiation of FOLFOX-4 / FOLFIRI therapy for the high increase group (n: 5) and the low increase group (n: 21) were 487 and 182 days, respectively, and was significantly better in the high increase group (p=0.004).
  • The alterations of hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were not observed.
  • CONCLUSIONS: It is suggested that serum-iron increase is a biological response not attributed to leakage from erythrocyte and hepatocyte.
  • Significantly better prognosis in high serum-iron group may suggest the usefulness of serum-iron level to distinguish responder and non-responder in FOLFOX-4/FOLFIRI therapy.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960858.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Sternberg CN, Szczylik C, Lee E, Salman PV, Mardiak J, Davis ID, Pandite L, Chen M, McCann L, Hawkins R: A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common laboratory abnormality was ALT elevation (53%; 10% Gr 3; 2% Gr 4).
  • CONCLUSIONS: Pazopanib monotherapy was well tolerated and demonstrated a significant improvement in PFS and RR compared to placebo.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962920.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Rougier P, Infante J, Van Laethem J, Stephenson JJ, Uronis H, Schwartzberg L, Chen L, Wu C, Smethurst D, Peeters M: A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results. J Clin Oncol; 2009 May 20;27(15_suppl):4130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In part 1, pts received pmab 6 mg/kg Q2W plus AMG 655 at a starting dose of 10 mg/kg (evaluation of subsequent doses of 3 mg/kg or 1 mg/kg if needed; 6-9 pts at each dose) by sequential intravenous infusion at week 1 and Q2W thereafter until PD or intolerability.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960839.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Fimmanò A, Coppola Bottazzi E, Cirillo C, Tammaro P, Casazza D: [Giant atypical muscle-involving lipoma of the right thigh: a case report and review of the literature]. Chir Ital; 2005 Nov-Dec;57(6):773-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant atypical muscle-involving lipoma of the right thigh: a case report and review of the literature].
  • [Transliterated title] Lipoma atipico gigante intramuscolare della coscia destra: caso clinico e analisi della letteratura.
  • The clinical case reported here concerns a giant lipoma (22 x 12 x 10 cm; 2740 g) located in the distal region of the right thigh, in a subfascial zone.
  • The histological findings indicated an atypical lipomatous tumour.
  • [MeSH-major] Lipoma. Soft Tissue Neoplasms. Thigh

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400775.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


65. Calò PG, Farris S, Tatti A, Tuveri M, Catani G, Nicolosi A: Primary mesenteric liposarcoma. Report of a case. G Chir; 2007 Aug-Sep;28(8-9):318-20
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mesenteric liposarcoma. Report of a case.
  • Primary mesenteric liposarcomas are very rare neoplasms.
  • The authors report a case of mesenteric liposarcoma recently observed.
  • On physical examination there was a large, well-circumscribed, abdominal mass.
  • Surgical excision with a tumour-free margin was achieved.
  • The histologic appearances were those of a well-differentiated liposarcoma (atypical lipomatous tumour).
  • Primary mesenteric liposarcoma is often resectable and requires aggressive surgical management; in consideration of the high risk of tumour recurrence, the treatment of choice is a wide surgical excision.
  • [MeSH-major] Liposarcoma. Mesentery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785044.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


66. Manduch M, Oliveira AM, Nascimento AG, Folpe AL: Massive localised lymphoedema: a clinicopathological study of 22 cases and review of the literature. J Clin Pathol; 2009 Sep;62(9):808-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 22 morbidly obese adults (mean patient weight 186 kg) presented with unilateral, large soft tissue lesions of longstanding duration.
  • Clinically, most lesions were regarded as representing benign processes, including pedunculated lipoma, lymphocoele or recurrent cellulites, although soft tissue sarcoma was also suspected in two cases.
  • Multinucleated fibroblastic cells, marked vascular proliferation, moderate stromal cellularity and fascicular growth raised concern among referring pathologists for atypical lipomatous tumour/well differentiated liposarcoma, angiosarcoma, and a fibroblastic neoplasm such as fibromatosis in 10, 2 and 1 case, respectively.
  • [MeSH-minor] Adult. Aged. Cellulitis / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Leg / pathology. Lipoma / diagnosis. Lymphocele / diagnosis. Male. Middle Aged. Obesity, Morbid / complications. Retrospective Studies. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734477.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


67. de Saint Aubain Somerhausen N, Coindre JM, Debiec-Rychter M, Delplace J, Sciot R: Lipoblastoma in adolescents and young adults: report of six cases with FISH analysis. Histopathology; 2008 Feb;52(3):294-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, there is some morphological overlap with atypical lipomatous tumour and myxoid liposarcoma and the age at presentation is often regarded as a major diagnostic criterion.
  • CONCLUSIONS: Lipoblastoma occurs rarely in young adults and should enter into the differential diagnosis of 'atypical' fatty tumours in adults.
  • [MeSH-major] DNA, Neoplasm / analysis. In Situ Hybridization, Fluorescence. Lipoma / genetics. Lipoma / pathology. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269579.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


68. Yoshida A, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H: Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol; 2010 Sep;34(9):1361-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant.
  • Mature bone formation in well-differentiated liposarcoma and dedifferentiated liposarcoma has been described as a reactive or "metaplastic" change in most reports, and its neoplastic nature has not been widely appreciated.
  • We herein describe 9 cases of well-differentiated/dedifferentiated liposarcoma with distinct areas of fibroosseous tissue histologically indistinguishable from low-grade osteosarcomas, that is, parosteal osteosarcoma or low-grade central osteosarcoma.
  • The tumors affected middle-aged to elderly patients, and occurred in the retroperitoneum and deep soft tissue of the extremities without connection to the skeletal system.
  • Grossly, all the tumors showed biphasic appearance with lipogenic and osteogenic area, the latter representing 5% to 50% of the total tumor volume.
  • Histologically, the lipogenic component exhibited typical histology of well-differentiated liposarcoma, whereas the osteogenic area consisted of fibroosseous tissue with numerous mature neoplastic bone trabeculae largely lacking osteoblastic rimming, with intervening fascicles of spindle cell proliferation showing low nuclear grade.
  • Recognition of this earlier underappreciated subtype of well-differentiated/dedifferentiated liposarcoma is important, because the fibroosseous component may seem so bland that it may be confused with benign metaplasia such as myositis ossificans, or conversely, the lipomatous component may be inconspicuous that it may be dismissed as normal fat, and such misinterpretation may potentially result in suboptimal treatment.
  • [MeSH-major] Bone Neoplasms / pathology. Liposarcoma / pathology. Neoplasms, Multiple Primary. Osteosarcoma / pathology. Retroperitoneal Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cyclin-Dependent Kinase 4 / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Proto-Oncogene Proteins c-mdm2 / metabolism. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697254.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


69. Kumagai K, Tomita M, Nozaki Y, Sugiyama K, Abe K, Uetani M: MRI findings of an inflammatory variant of well-differentiated liposarcoma. Skeletal Radiol; 2010 May;39(5):491-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI findings of an inflammatory variant of well-differentiated liposarcoma.
  • The inflammatory variant of well-differentiated liposarcoma (WDLPS) is a rare subtype.
  • We present a 75-year-old woman who had a tumor that was difficult to diagnose preoperatively.
  • Magnetic resonance imaging of the tumor revealed a large, lobulated heterogeneous soft tissue mass with a distinctive pattern of intermingled well-differentiated fatty elements and nodular areas of high T2-intensity tissue.
  • [MeSH-major] Liposarcoma / complications. Liposarcoma / pathology. Magnetic Resonance Imaging / methods. Muscle Neoplasms / complications. Muscle Neoplasms / pathology. Myositis / etiology. Myositis / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Myositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Med. 2008 Aug;26(7):450-3 [18770006.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):535-43 [10947023.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jan;128(1):e21-2 [14692832.001]
  • [Cites] Ophthalmology. 1989 Feb;96(2):180-91 [2704536.001]
  • [Cites] Indian J Cancer. 2006 Jan-Mar;43(1):36-8 [16763361.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):884-95 [9255251.001]
  • [Cites] Ann Diagn Pathol. 2000 Aug;4(4):252-66 [10982304.001]
  • [Cites] J Assoc Physicians India. 2001 Jul;49:761-3 [11573568.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):258-62 [11757865.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jul;36(7):462-7 [16887838.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):518-27 [9158675.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):1005-15 [6277453.001]
  • (PMID = 20054537.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 12
  •  go-up   go-down


70. Shimada S, Harada H, Ishizawa K, Hirose T: Retroperitoneal lipomatous angiomyolipoma associated with amyloid deposition masquerading as well-differentiated liposarcoma. Pathol Int; 2006 Oct;56(10):638-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lipomatous angiomyolipoma associated with amyloid deposition masquerading as well-differentiated liposarcoma.
  • Reported herein is a case of retroperitoneal angiomyolipoma associated with amyloid deposition, masquerading as well-differentiated liposarcoma.
  • A 16 x 13 cm lipomatous tumor was resected from the perirenal retroperitoneum of a 71-year-old woman.
  • Microscopically, the tumor was exclusively composed of mature adipose tissue and abnormal thick blood vessels, but bundles of smooth muscle were lacking.
  • Initially, well-differentiated liposarcoma was highly suspected.
  • Real-time polymerase chain reaction failed to demonstrate the amplification of the murine double-minute type 2 gene and cyclin-dependent kinase 4 gene in this tumor.
  • Therefore, the tumor was diagnosed as lipomatous angiomyolipoma.
  • After the diagnosis, it was found that the patient had multiple myeloma and cardiac amyloidosis, suggesting that the amyloid deposition within the tumor was a complication of the myeloma.
  • Lipomatous angiomyolipoma may be a diagnostic pitfall of retroperitoneal lipomatous tumors.
  • [MeSH-major] Amyloid / metabolism. Angiomyolipoma / diagnosis. Angiomyolipoma / metabolism. Liposarcoma / diagnosis. Liposarcoma / metabolism. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / metabolism

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984623.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Amyloid; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


71. Muddaiah A, Zaffarullah W, Tewary A: Recurrent well-differentiated liposarcoma of the larynx: a case report and review of literature. Eur Arch Otorhinolaryngol; 2010 Jul;267(7):1163-5
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent well-differentiated liposarcoma of the larynx: a case report and review of literature.
  • We present a rare case of recurrent well-differentiated liposarcoma, which re-occurred 26 years after initial presentation, having presented non-acutely on both occasions with dyspnoea, progressive dysphonia and intermittent stridor due to a valve-like laryngeal obstruction happening mainly when supine.
  • We have discussed management of these recurrent well-differentiated liposarcomas of the larynx including the adequacy of local versus radical treatment with review of literature which reveals that only nine cases have been reported so far.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Liposarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 2007 Jun;116(6):418-24 [17672243.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Dec;112(12):1289-92 [3768156.001]
  • [Cites] J Laryngol Otol. 2001 Jul;115(7):593-5 [11485600.001]
  • [Cites] Am J Surg Pathol. 1990 Feb;14(2):134-41 [2301699.001]
  • [Cites] J Laryngol Otol. 1998 Sep;112(9):880-2 [9876384.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1998 Jun;107(6):540-6 [9635467.001]
  • [Cites] Arch Pathol Lab Med. 1985 Mar;109(3):294-6 [3838462.001]
  • [Cites] ANZ J Surg. 2005 Sep;75(9):803-6 [16173997.001]
  • [Cites] Laryngoscope. 1999 Aug;109(8):1245-52 [10443828.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Dec;23(4):291-9 [3779625.001]
  • [Cites] Laryngoscope. 1995 Jul;105(7 Pt 1):747-56 [7603280.001]
  • (PMID = 20437051.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 12
  •  go-up   go-down


72. Kim JL, Woo JY, Lee MJ, Kim KR, Jung JP, Lee NJ, Choi SH, Kim HD, Yang I, Chung SY: Imaging findings of primary well-differentiated liposarcoma of the liver: a case report. Acta Radiol; 2007 Dec;48(10):1061-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings of primary well-differentiated liposarcoma of the liver: a case report.
  • Primary liposarcoma of the liver is extremely rare.
  • We report here on a case of primary well-differentiated liposarcoma in the left hepatic lobe of a 63-year-old woman.
  • Abdominal ultrasonography showed a well-defined, echogenic, round mass.
  • The resected tumor appeared as a well-defined, round, tan-yellow mass.
  • Histological analysis showed a well-differentiated liposarcoma.
  • [MeSH-major] Diagnostic Imaging. Liposarcoma / diagnosis. Liver Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18038349.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


73. Yildirim O, Namdaroglu OB, Menekse E, Albayrak AL: Giant well-differentiated liposarcoma of retroperitoneum. Bratisl Lek Listy; 2008;109(9):418-20
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant well-differentiated liposarcoma of retroperitoneum.
  • Liposarcoma is a malignancy of fat cells that occurs in deep soft tissue and mostly seen in limbs and retroperitoneum.
  • It is the most common mesenchymal tumor of the retroperitoneum.
  • It is detected at very late stages especially when the tumor gains substantial size, weight of several pounds at the time of diagnosis because it is grows very silently in deep tissues in the retroperitoneal area.
  • Therefore, most of the patients with liposarcoma have no symptoms until the tumor is getting very large and pressurizes on neighboring structures which causes tenderness, pain, or functional disturbances.
  • At laparotomy the retroperitoneal tumor weighed 13.2 kg, Histologically it was a well-differentiated liposarcoma.
  • Total extirpation surgery is still the most effective treatment in well-differentiated liposarcomas.
  • [MeSH-major] Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040150.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


74. Arakaki R, Yoshikawa T, Yamada H, Kamoto T, Mikami Y: [A case of retroperitoneal well-differentiated liposarcoma with metaplastic bone formation]. Hinyokika Kiyo; 2010 Dec;56(12):697-700
Genetic Alliance. consumer health - Retroperitoneal liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal well-differentiated liposarcoma with metaplastic bone formation].
  • Computed tomography and magnetic resonance imaging showed a huge tumor in the right retroperitoneal space, which adhered to the right kidney.
  • Histological examination revealed well differentiated liposarcoma with metaplastic bone formation.
  • A retoroperitoneal liposarcoma with metaplastic bone formation is rare.
  • [MeSH-major] Bone and Bones / pathology. Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21273809.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


75. Paragis Sanchez T, Bannwart C, Murilo Araújo D, Dos Santos Pinto Júnior D, Thomé Capuano AC: Well-differentiated liposarcoma of the tongue. A case report. Minerva Stomatol; 2008 Jul-Aug;57(7-8):383-7
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated liposarcoma of the tongue. A case report.
  • Liposarcoma of the oral cavity is very rare.
  • The difficulty in clinical and histopatologic differentiation of these oral lipomatous lesions have been recognized by several authors.
  • The aim of this article is to present a case report of a well-differentiated lipoma-like liposarcoma of the tongue, in a 36-year-old woman, and to review the existing literature.
  • [MeSH-major] Liposarcoma / pathology. Tongue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18784638.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 29
  •  go-up   go-down


76. Jakowski JD, Wakely PE Jr: Rhabdomyomatous well-differentiated liposarcoma arising in giant fibrovascular polyp of the esophagus. Ann Diagn Pathol; 2009 Aug;13(4):263-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyomatous well-differentiated liposarcoma arising in giant fibrovascular polyp of the esophagus.
  • We report an example of an esophageal giant fibrovascular polyp harboring a well-differentiated liposarcoma with rhabdomyomatous differentiation in a 68 year-old man.
  • Surgical resection revealed a 15-cm smooth-surfaced club-shaped mass composed of a well-differentiated liposarcoma demonstrating myoglobin, muscle-specific actin, and myogenin-positive rhabdomyomatous differentiation.
  • To date, no previously reported giant fibrovascular polyp case has described a liposarcoma with rhabdomyomatous change.
  • [MeSH-major] Esophageal Neoplasms / pathology. Liposarcoma / pathology. Polyps / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19608085.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Myogenin; 0 / Myoglobin
  •  go-up   go-down


77. Weaver J, Rao P, Goldblum JR, Joyce MJ, Turner SL, Lazar AJ, López-Terada D, Tubbs RR, Rubin BP: Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma? Mod Pathol; 2010 Oct;23(10):1301-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?
  • Well-differentiated liposarcoma/atypical lipomatous tumor can be difficult to differentiate from benign lipomatous tumors, especially on limited biopsy material.
  • Adjunctive tests for MDM2 (murine double minute 2) have proven useful in whole-tissue sections; however, their utility has not been determined within the increasingly popular core needle biopsy.
  • Herein, we compare the ability of MDM2 immunohistochemistry and MDM2 fluorescence in situ hybridization (FISH) to discriminate benign lipomatous tumors from well-differentiated liposarcoma on core needle biopsies.
  • Well-differentiated liposarcoma (n=17) and an assortment of benign lipomatous tumors (n=37), which had concurrent or previous core needle biopsies, and resection specimens were subjected to both MDM2 immunohistochemistry and MDM2 FISH on both whole-tissue sections and corresponding core needle biopsy sections.
  • Percentage tumor cells positive for MDM2 by immunohistochemistry and an MDM2:CEP12 FISH ratio was calculated in each biopsy and resection specimen pair and the results were compared.
  • The average MDM2:CEP12 ratio was similar in the biopsy material compared with the whole-tissue sections in both well-differentiated liposarcoma and the benign lipomatous tumor group of neoplasms.
  • Detection of MDM2 amplification by FISH is a more sensitive and specific adjunctive test than MDM2 immunohistochemistry to differentiate well-differentiated liposarcoma from various benign lipomatous tumors, especially on limited tissue samples.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy, Needle. Liposarcoma / diagnosis. Proto-Oncogene Proteins c-mdm2 / biosynthesis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lipoma / diagnosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495536.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


78. Meloni F, Feo CF, Profili S, Cossu ML, Meloni GB: Omental Well-Differentiated Liposarcoma: US, CT and MR Findings. Int J Biomed Sci; 2009 Sep;5(3):302-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental Well-Differentiated Liposarcoma: US, CT and MR Findings.
  • Liposarcomas are the most common of sarcoma tumours, they are usually located in the lower limbs, retroperitoneum, or abdominal cavity; up to date, only a few cases of omental liposarcoma with different histotype have been described.
  • We present a case of omental well-differentiated liposarcoma and discuss imaging findings on ultrasound, computed tomography, and magnetic resonance to differentiate omental liposarcomas from other abdominal tumour entities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23675151.001).
  • [ISSN] 1550-9702
  • [Journal-full-title] International journal of biomedical science : IJBS
  • [ISO-abbreviation] Int J Biomed Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3614784
  • [Keywords] NOTNLM ; computed tomography / liposarcoma / magnetic resonance / omentum / ultrasound
  •  go-up   go-down


79. Tanas MR, Sthapanachai C, Nonaka D, Melamed J, Oliveira AM, Erickson-Johnson MR, Rubin BP: Pseudosarcomatous fibroblastic/myofibroblastic proliferation in perinephric adipose tissue adjacent to renal cell carcinoma: a lesion mimicking well-differentiated liposarcoma. Mod Pathol; 2009 Sep;22(9):1196-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudosarcomatous fibroblastic/myofibroblastic proliferation in perinephric adipose tissue adjacent to renal cell carcinoma: a lesion mimicking well-differentiated liposarcoma.
  • Cytologically atypical stromal cells were found in the perinephric adipose tissue, mimicking well-differentiated liposarcoma in 12 of 59 (20%) consecutive nephrectomy specimens that were resected for renal cell carcinoma.
  • Morphologically, the atypical cells included enlarged, hyperchromatic spindle cells and floret-type multinucleate cells.
  • Of 59, 10 (17%) renal cell carcinomas invaded through the renal capsule into the perinephric adipose tissue.
  • Of these cases, three (30%) contained the aforementioned atypical cells.
  • In contrast, 9 of 49 cases without extrarenal invasion (18%) contained the atypical stromal cells.
  • Of the 12 cases with atypical stromal cells, 3 (25%) were associated with extrarenal involvement.
  • The atypical spindle cells exhibited focal to variable positivity for smooth muscle actin and desmin in 3 of the 14 cases (including two cases from our consultation files) each.
  • Amplification of MDM2 gene region, which is commonly observed in well-differentiated liposarcoma, was absent by fluorescence in situ hybridization (FISH) in the atypical stromal cells.
  • Immunohistochemistry and FISH suggest that the atypical cells are most consistent with reactive fibroblasts/myofibroblasts.
  • Recognition of these atypical fibroblasts/myofibroblasts may help in avoiding the potential pitfall of misdiagnosing them as well-differentiated liposarcoma.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Fibroblasts / pathology. Kidney Neoplasms / pathology. Liposarcoma / pathology
  • [MeSH-minor] Adipose Tissue / pathology. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19525929.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Hansch A, Gajda M, Boettcher J, Pfeil A, Kaiser WA: Incomplete paresis of the sciatic nerve due to massive atypical lipoma of the pelvis: a case report. Cases J; 2008;1(1):296

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete paresis of the sciatic nerve due to massive atypical lipoma of the pelvis: a case report.
  • BACKGROUND: Liposarcomas are classified into four subtypes, with different malignancy potential and characteristic imaging appearances.
  • Well-differentiated liposarcomas have imaging characteristics similar to those of benign lipomas, however they can be usually distinguished from lipomas because of the larger size and broader fibrous septa, with a more nodular appearance.
  • CASE PRESENTATION: This paper presents a case of atypical lipoma (well-differentiated liposarcoma) of the pelvis, leading to partial involvement of the sciatic nerve.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 2005 Jan-Feb;25(1):69-85 [15653588.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:67-74 [10095419.001]
  • [Cites] Skeletal Radiol. 1990;19(5):359-62 [2377902.001]
  • [Cites] Radiology. 1993 Feb;186(2):455-9 [8421750.001]
  • [Cites] Radiographics. 1991 Jan;11(1):81-106 [1996399.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):589-94 [9242783.001]
  • (PMID = 18983660.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584648
  •  go-up   go-down


81. Weaver J, Goldblum JR, Turner S, Tubbs RR, Wang WL, Lazar AJ, Rubin BP: Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol; 2009 Jan;22(1):66-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.
  • Inflammatory liposarcoma is a variant of well-differentiated liposarcoma/atypical lipomatous tumor that consists of a mixture of lymphocytes, histiocytes, scattered atypical stromal cells, mature adipocytes, and rarely lipoblasts.
  • Well-differentiated liposarcoma/atypical lipomatous tumor and dedifferentiated liposarcoma have characteristic molecular markers in the form of giant marker and ring chromosomes consisting of amplicons of 12q13-15, which includes MDM2.
  • MDM2 immunohistochemistry (IHC) (Zymed; clone IF2) and dual color fluorescence in situ hybridization utilizing MDM2 (12q15) and chromosome 12 centromeric probes were performed on formalin-fixed and paraffin-embedded specimens from inflammatory well-differentiated liposarcoma (17 cases), sclerosing mesenteritis (14 cases), and idiopathic retroperitoneal fibrosis (10 cases).
  • MDM2 expression as detected by IHC is a very sensitive tool in recognizing inflammatory well-differentiated liposarcoma (17 of 17); however, 21% (3 of 14) and 10% (1 of 10) of sclerosing mesenteritis and retroperitoneal fibrosis, respectively, displayed weak MDM2 immunoexpression.
  • The MDM2 fluorescence in situ hybridization assay was very specific for inflammatory well-differentiated liposarcoma as 15 of 17 (88%) cases showed MDM2 amplification, whereas none of the cases of sclerosing mesenteritis or idiopathic retroperitoneal fibrosis showed amplification.
  • Increased MDM2 expression and/or MDM2 amplification can be employed to aid discrimination of inflammatory well-differentiated liposarcoma from fibroinflammatory mimics.
  • However, lack of MDM2 immunoexpression would rule out the possibility of inflammatory well-differentiated liposarcoma.
  • [MeSH-major] Biomarkers, Tumor / genetics. Liposarcoma / diagnosis. Panniculitis, Peritoneal / diagnosis. Proto-Oncogene Proteins c-mdm2 / genetics. Retroperitoneal Fibrosis / diagnosis


82. Trahan S, Erickson-Johnson MR, Rodriguez F, Aubry MC, Cheville JC, Myers JL, Oliveira AM: Formation of the 12q14-q15 amplicon precedes the development of a well-differentiated liposarcoma arising from a nonchondroid pulmonary hamartoma. Am J Surg Pathol; 2006 Oct;30(10):1326-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formation of the 12q14-q15 amplicon precedes the development of a well-differentiated liposarcoma arising from a nonchondroid pulmonary hamartoma.
  • Herein, we report a 48-year-old woman with a history of an incomplete excised nonchondroid pulmonary hamartoma presenting as an indolent tumor recurrence.
  • Excision of the tumor revealed a well-differentiated liposarcoma arising from the hamartomatous component.
  • MDM2 and HMGA2 amplification were found in a subset of stromal cells in the hamartomatous component and in most cells of the well-differentiated liposarcoma.
  • These findings suggest that the formation of the 12q14-q15 chromosome amplicon, the characteristic cytogenetic finding of well-differentiated liposarcomas and the structural genomic component of the supernumerary ring and giant rod chromosomes, occurred before the morphologic changes characteristic of these malignant adipose tissue tumors and likely represents a very early molecular event in their development.
  • [MeSH-major] Chromosomes, Human, Pair 12. Gene Amplification. Hamartoma / genetics. Liposarcoma / genetics. Lung Neoplasms / genetics

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001166.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / HMGA2 Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


83. Erickson-Johnson MR, Seys AR, Roth CW, King AA, Hulshizer RL, Wang X, Asmann YW, Lloyd RV, Jacob EK, Oliveira AM: Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol; 2009 Dec;22(12):1541-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma.
  • The discrimination between well-differentiated liposarcomas/atypical lipomatous tumors and lipomas can be diagnostically challenging at the histological level.
  • However, cytogenetic identification of ring and giant rod chromosomes supports the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumor.
  • MDM2 is consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors, and up to 25% in other sarcomas.
  • As part of a large genomic study of lipomatous neoplasms, we initially found CPM to be consistently amplified in well-differentiated liposarcomas/atypical lipomatous tumors.
  • To further explore this initial finding, we investigated the copy number status of MDM2 and CPM by fluorescent in situ hybridization (FISH) on a series of 138 tumors and 17 normal tissues, including 32 well-differentiated liposarcoma/atypical lipomatous tumors, 63 lipomas, 11 pleomorphic lipomas, 2 lipoblastomas, 30 other tumors and 17 normal fat samples.
  • All 32 well-differentiated liposarcoma/atypical lipomatous tumors showed amplification of MDM2 and CPM, usually >20 copies per cell.
  • These findings suggest that identification of CPM amplification could be used as an alternative diagnostic tool for the diagnosis of well-differentiated liposarcoma/atypical lipomatous tumors.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cell Differentiation. Gene Amplification. Lipoma / diagnosis. Liposarcoma / diagnosis. Metalloendopeptidases / genetics

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820690.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; EC 3.4.17.12 / carboxypeptidase M; EC 3.4.24.- / Metalloendopeptidases; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


84. Coindre JM, Pédeutour F, Aurias A: Well-differentiated and dedifferentiated liposarcomas. Virchows Arch; 2010 Feb;456(2):167-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated and dedifferentiated liposarcomas.
  • Atypical lipomatous tumor or well-differentiated liposarcoma (ALT-WDLPS) and dedifferentiated liposarcoma (DDLPS) share the same basic genetic abnormality characterized by a simple genomic profile with a 12q14-15 amplification involving MDM2 gene.
  • This paper reviews the molecular pathology, general clinical and imaging features, histopathology, new diagnostic tools, and prognosis of ALT-WDLPS and DDLPS.
  • [MeSH-major] Liposarcoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10 ):1557-66 [17895758.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Nov;155(1):1-24 [15527898.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87 [11960696.001]
  • [Cites] Cell Biol Int. 2007 Jun;31(6):586-91 [17240171.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):945-55 [9706974.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10 ):1476-89 [17895748.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1657-65 [18704991.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] Histopathology. 2007 Sep;51(3):422-6 [17727490.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1770-83 [16603719.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):256-62 [12640106.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):15-29 [10721693.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10 ):1340-7 [16160477.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] Am J Surg Pathol. 1993 Jun;17(6):546-56 [8333554.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10 ):2233-41 [18214854.001]
  • [Cites] Oncogene. 2004 Jun 10;23(27):4673-80 [15122339.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):32-7 [15034865.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Oct;29(2):117-29 [10959091.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):361-74 [17418412.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):24-9 [12547153.001]
  • [Cites] Cancer Lett. 2009 Jan 18;273(2):323-30 [18823700.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):30-41 [9892106.001]
  • [Cites] Bull Cancer. 2004 Apr;91(4):317-23 [15242313.001]
  • [Cites] Cancer. 1979 Feb;43(2):574-84 [421182.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):407-16 [16415793.001]
  • [Cites] Histopathology. 1998 Nov;33(5):414-24 [9839165.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):176-81 [15702084.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):199-205 [17354236.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jun;10(2):85-94 [7520271.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1213-23 [7977944.001]
  • [Cites] Histopathology. 1997 Jun;30(6):507-11 [9205853.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14 ):6626-36 [17638873.001]
  • [Cites] Am J Surg Pathol. 1987 Mar;11(3):161-83 [3826477.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):518-27 [9158675.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):381-91 [16926564.001]
  • [Cites] Am J Surg Pathol. 1992 Nov;16(11):1051-8 [1471725.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):943-9 [18500263.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1271-5 [10755400.001]
  • [Cites] J Pathol. 2004 Jul;203(3):822-30 [15221942.001]
  • (PMID = 19688222.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Number-of-references] 46
  •  go-up   go-down


85. Nishida J, Morita T, Ogose A, Okada K, Kakizaki H, Tajino T, Hatori M, Orui H, Ehara S, Satoh T, Shimamura T: Imaging characteristics of deep-seated lipomatous tumors: intramuscular lipoma, intermuscular lipoma, and lipoma-like liposarcoma. J Orthop Sci; 2007 Nov;12(6):533-41
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics of deep-seated lipomatous tumors: intramuscular lipoma, intermuscular lipoma, and lipoma-like liposarcoma.
  • BACKGROUND: Lipoma-like liposarcomas mimic deep-seated lipomas in regard to imaging as well as histological findings and occasionally cause problems concerning diagnosis and treatment.
  • The differences in the imaging findings among these lesions are not well defined.
  • The purpose of this study was to elucidate the differences among the deep-seated adipocytic neoplasms including intramuscular lipoma, intermuscular lipoma, and lipoma-like liposarcoma.
  • METHODS: The imaging and clinicopathological findings of 40 intramuscular lipomas, 27 intermuscular lipomas, and 22 lipoma-like liposarcomas were evaluated, and the possibilities in the differential diagnosis were assessed.
  • RESULTS: Although the most frequent symptom was a palpable mass, swelling was a common symptom of intramuscular lipomas and lipoma-like liposarcomas.
  • Imaging studies revealed dumbbell-shaped appearances among intermuscular lipomas, whereas spherical masses were characteristic of intramuscular lipomas and lipoma-like liposarcomas.
  • Computed tomography and magnetic resonance imaging revealed fatty lesions containing streaky structures in benign lesions, and CT revealed foci of hazy amorphous density, representing spindle cell proliferation, in lipoma-like liposarcoma.
  • Although streaky structures corresponding to entrapped muscle fibers were thick and occasionally interrupted in intramuscular lipomas, the streaky structures corresponding to areolar fibrous tissue were thin and were usually not interrupted in intermuscular lipomas.
  • In lipoma-like well-differentiated liposarcomas, thick streaks represented entrapped muscle fibers, and thin streaks represented fibrous tissue or neoplastic spindle cell proliferation.
  • [MeSH-major] Lipoma / diagnosis. Liposarcoma / diagnosis. Magnetic Resonance Imaging / methods. Muscle Neoplasms / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040635.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


86. Micci F, Bjerkehagen B, Heim S: Pairwise comparison of genomic imbalances between primary and recurrent well differentiated liposarcomas. Cancer Genet Cytogenet; 2007 Oct 15;178(2):163-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pairwise comparison of genomic imbalances between primary and recurrent well differentiated liposarcomas.
  • Well-differentiated liposarcomas (WDL) are intermediate malignant, locally aggressive mesenchymal neoplasms.
  • The cytogenetic hallmarks of WDL are supernumerary rings and giant marker chromosomes containing material mainly from chromosome arms 1q and especially 12q, but also occasionally from other chromosomes.
  • WDL are typical examples of tumors that may become more aggressive with time.
  • One would assume that additional genomic changes lie behind the acquisition of such a more dangerous phenotype, and yet very little is known about the putative, late-occurring genomic aberrations in recurrent WDL.
  • We have undertaken a pairwise comparison of the genomic imbalances occurring in primary and recurrent WDL from the same patient.
  • In one of the cases, the patient's final recurrence, which was 17 years after the primary tumor and showed more pronounced nuclear atypia, had seven additional genomic changes compared with what was found in the primary tumor.
  • The findings illustrate that the phenotypic changes some WDL undergo with time may have a genomic correlate, and that a pathogenetic continuum exists between WDL and dedifferentiated, more malignant liposarcomas.
  • [MeSH-major] Allelic Imbalance. Liposarcoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954275.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Mica L, Gianom D, Bode B, Jaklin P, Hollinger A: Rare cause of dysphagy: giant polypoid esophageal well-differentiated liposarcoma. Case Rep Gastroenterol; 2007;1(1):7-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare cause of dysphagy: giant polypoid esophageal well-differentiated liposarcoma.
  • Liposarcoma represents one of the most frequent (10-20%) malignant mesenchymal tumors in the adult, affecting mostly the soft tissue of extremities, the trunk or the retroperitoneum.
  • This tumor type occurs exceptionally rarely in the gastrointestinal tract with only few cases described in the literature.
  • CT scan of the upper gastrointestinal tract revealed a large esophageal tumor filling out the whole length of the esophagus.
  • The tumor was removed by parasternocleidomastoidal approach with a stapler.
  • Histopathological examination revealed a well-differentiated liposarcoma (grade I).
  • Well-differentiated liposarcomas are characterised by amplified material of the 12q13-15 chromosomal region, present in the form of giant or ring chromosomes and leading to the overexpression of MDM2 and CDK4 genes.
  • MDM2 and CDK4 proteins can be detected immunhistochemically, which was the case in the reported tumor.
  • Overexpression of these proteins leads to suppression of tumor suppressor genes, leading to increased cell survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Esophagus. 1998 Jan;11(1):68-71 [9595239.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Aug;116(2):365-7 [9699597.001]
  • [Cites] World J Gastroenterol. 2006 Feb 21;12(7):1149-52 [16534863.001]
  • [Cites] Eur J Surg Oncol. 1991 Jun;17(3):313-5 [2044787.001]
  • [Cites] Clin Radiol. 1990 Nov;42(5):356-8 [2245576.001]
  • [Cites] Korean J Intern Med. 1989 Jan;4(1):86-9 [2487410.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Sep;86(3):447-50 [6887958.001]
  • [Cites] Diagn Mol Pathol. 1997 Oct;6(5):249-54 [9458382.001]
  • [Cites] Laryngoscope. 1999 Aug;109(8):1245-52 [10443828.001]
  • [Cites] J Thorac Imaging. 1999 Oct;14(4):316-9 [10524816.001]
  • [Cites] Can J Gastroenterol. 2002 Jun;16(6):377-9 [12096301.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Mar;4(3):192-201 [12612638.001]
  • [Cites] Yonsei Med J. 2003 Aug 30;44(4):715-8 [12950130.001]
  • [Cites] J Am Coll Surg. 2004 Feb;198(2):320-1 [14964253.001]
  • [Cites] Ann Thorac Surg. 1991 Jun;51(6):1012-3 [2039300.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):398-407 [9164509.001]
  • [Cites] Arch Pathol Lab Med. 2004 Aug;128(8):922-5 [15270604.001]
  • (PMID = 21487465.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3073781
  • [Keywords] NOTNLM ; CDK4 / Esophagus / MDM2 / Well-differentiated polypoid liposarcoma
  •  go-up   go-down


88. Italiano A, Maire G, Sirvent N, Nuin PA, Keslair F, Foa C, Louis C, Aurias A, Pedeutour F: Variability of origin for the neocentromeric sequences in analphoid supernumerary marker chromosomes of well-differentiated liposarcomas. Cancer Lett; 2009 Jan 18;273(2):323-30
Cellosaurus - a cell line knowledge resource. culture/stock collections - 94T779 (CVCL_U614) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variability of origin for the neocentromeric sequences in analphoid supernumerary marker chromosomes of well-differentiated liposarcomas.
  • Well-differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas are cytogenetically characterized by the presence of supernumerary ring or giant chromosomes containing amplified material from the 12q14-15 region.
  • WDLPS is the sole solid tumor for which the presence of a neocentromere is a consistent and specific feature.
  • By immunostaining with anti-centromere antibodies in combination with FISH analysis (immunoFISH) in four cases of WDLPS, we have shown that sequences from the region 12q14-21 region were not located at the neocentromere site.
  • In addition, we have microdissected the neocentromeric region from a giant supernumerary chromosome in the 94T778 WDLPS cell line.
  • We have observed that this 4p sequence was not involved in the neocentromere of the supernumerary giant chromosome present in the 93T449 WDLPS cell line derived from a metachronous recurrence of the same primary WDLPS than 94T778.
  • Altogether, these results indicate that the neocentromeres in WDLPS originate from amplified chromosomal regions other than 12q14-15 and do not involve a specific and recurrent DNA sequence.
  • [MeSH-major] Centromere / ultrastructure. Chromosomes / ultrastructure. Liposarcoma / genetics

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - 94T778 (CVCL_U613) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18823700.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


89. Cappellani A, Zanghì A, Di Vita M, La Porta D, Alfano G, D'Angelo AF: Very atypical presentation of a retroperitoneal "atypical lipoma". A well differentiated liposarcoma presenting as sciatic hernia. Ann Ital Chir; 2007 Jan-Feb;78(1):69-72
MedlinePlus Health Information. consumer health - Hernia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very atypical presentation of a retroperitoneal "atypical lipoma". A well differentiated liposarcoma presenting as sciatic hernia.
  • Unlike hernias and neoplasms of any other body site, the sciatic hernia is uncommon and the finding of an atypical lipoma in it is probably unique.
  • A CT scan must be considered any time a rare form of hernia is observed and the surgical treatment of a retroperitoneal lipoma has to be radical, to prevent a recurrence.
  • This is the strategy followed by the authors in a case of a 53 year old lady presenting with a large retroperitoneal lipomatous neoplasm within a sciatic hernia.
  • [MeSH-major] Hernia / etiology. Lipoma / diagnosis. Liposarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis. Sciatic Nerve

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17518336.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


90. Danzi M, Grimaldi L, Reggio S, Danzi R: [Giant atypical lipoma of the thigh. Case report and literature review]. G Chir; 2010 Mar;31(3):108-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant atypical lipoma of the thigh. Case report and literature review].
  • [Transliterated title] Lipoma atipico gigante della coscia. Caso clinico e revisione della letteratura.
  • Lipomas are benign tumors of mesenchymal origin which may localize in various sites, both superficial or deep.
  • The Authors report the case of a 73 years old woman, with a large swelling localized at the anterior-medial region of the left thigh, of about three years, completely asymptomatic, surgically excised, and by histological examination, proved to be a giant atypical lipoma.
  • [MeSH-major] Lipoma / pathology. Lipoma / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Thigh

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426923.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 22
  •  go-up   go-down


91. Smith MA, Kluck E, Jagannath S, Yang SC: Giant multi-polypoid liposarcoma of the esophagus: an atypical presentation. Ann Thorac Surg; 2010 Feb;89(2):610-2
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant multi-polypoid liposarcoma of the esophagus: an atypical presentation.
  • Liposarcomas of the esophagus are rare with only 19 cases reported in the English literature.
  • We present a giant, well-differentiated liposarcoma of the esophagus with multiple pedunculated polypoid-like growths, which made it radiographically and pathologically noncharacteristic.
  • [MeSH-major] Deglutition Disorders / etiology. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / surgery. Hoarseness / etiology. Liposarcoma / diagnosis. Liposarcoma / surgery. Neoplasm, Residual / diagnosis. Neoplasm, Residual / surgery. Polyps / diagnosis. Polyps / surgery. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Respiratory Sounds / etiology

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20103356.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Jakobiec FA, Nguyen J, Bhat P, Fay A: MDM2-positive atypical lipomatous neoplasm/well-differentiated liposarcoma versus spindle cell lipoma of the orbit. Ophthal Plast Reconstr Surg; 2010 Nov-Dec;26(6):413-5
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDM2-positive atypical lipomatous neoplasm/well-differentiated liposarcoma versus spindle cell lipoma of the orbit.
  • PURPOSE: To distinguish, in a 36-year-old man, an atypical lipomatous neoplasm/well-differentiated liposarcoma from a spindle cell lipoma in a recurrent orbital tumor.
  • RESULTS: MDM2 gene amplification was discovered in the CD34 tumor cells.
  • These findings established the diagnosis of a well-differentiated liposarcoma with lipoma-like and spindle cell features and ruled out a spindle cell lipoma.
  • CONCLUSION: Well-differentiated liposarcoma is a slow growing, infiltrative, and nonmetastasizing neoplasm that is microscopically and diagnostically challenging.
  • It can be reliably separated from a benign spindle cell or an atypical lipoma by using the markers MDM2 and Ki-67.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lipoma / diagnosis. Liposarcoma / diagnosis. Orbital Neoplasms / diagnosis. Proto-Oncogene Proteins c-mdm2 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20639786.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / S100 Proteins; 9013-56-3 / Factor XIII; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


93. Serpell JW, Chen RY: Review of large deep lipomatous tumours. ANZ J Surg; 2007 Jul;77(7):524-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of large deep lipomatous tumours.
  • BACKGROUND: Lipomatous tumours comprise a range of diagnoses.
  • METHODS: Retrospective review of 224 soft tissue tumours from the Senior Author's (J. W.
  • S.) database identified 28 patients with deep lipomatous tumours.
  • RESULTS: Eleven deep lipomas, six deep atypical lipomas, four well-differentiated (lipoma-like) liposarcomas, three well-differentiated liposarcomas and four liposarcomas were studied.
  • All patients diagnosed with deep lipoma and deep atypical lipoma underwent marginal excision.
  • The median size of the excised tumour was 11 cm.
  • Recurrence occurred in three deep atypical lipomas and one liposarcoma.
  • Dedifferentiation occurred in one deep atypical lipoma, which transformed into a liposarcoma.
  • CONCLUSION: Large deep lipomatous tumours are uncommon and although they do not tend to metastasize, they not infrequently recur locally.
  • Key aspects in achieving a complete, but marginal resection of the deep atypical lipoma and the well-differentiated lipoma-like liposarcoma is accurate preoperative diagnosis with core biopsy and accurate imaging to assess deep unsuspected extensions of the tumour.
  • [MeSH-major] Lipoma / surgery. Liposarcoma / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2007 Dec;77(12):1129 [17973678.001]
  • (PMID = 17610686.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


94. Gupta R, Sharma A, Arora R, Kulkarni MP, Chattopadhaya TK, Singh MK: Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist. J Gastrointest Cancer; 2010 Mar;41(1):79-83
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist.
  • BACKGROUND: Mesenteric liposarcoma is a rare intra-abdominal sarcoma with very few cases reported in the available English literature.
  • Incomplete resection of the tumor leads to recurrence, and recurrent tumors carry a risk of dedifferentiation.
  • Dedifferentiation in liposarcoma manifests as a nonlipogenic sarcoma, which is usually high-grade and may show osteosarcomatous differentiation rarely.
  • To the best of our knowledge, osteoid metaplasia in a well-differentiated liposarcoma without evidence of dedifferentiation has not been documented in the available literature.
  • CASE: We describe the case of a middle-aged adult man with a well-differentiated liposarcoma of the mesentery.
  • The patient presented with a recurrent tumor 5 years after the initial surgery.
  • At recurrence, the histological features were those of a well-differentiated liposarcoma with focal osseous metaplasia without any evidence of dedifferentiation in the extensive sections examined.
  • CONCLUSION: Osseous metaplasia is a rare phenomenon in lipomas and dedifferentiated liposarcomas.
  • Such an occurrence in a recurrent well-differentiated liposarcoma is a perplexing problem due to the potential confusion with dedifferentiation.
  • [MeSH-major] Calcinosis / pathology. Liposarcoma / pathology. Mesentery / pathology. Neoplasm Recurrence, Local / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058101.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Tayal S, Classen E, Bemis L, Robinson WA: C-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis. Anticancer Res; 2005 May-Jun;25(3B):2215-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis.
  • In gastrointestinal stromal tumors (GISTs), an activating mutation in c-kit predicts treatment response; its presence in other soft tissue tumors is unexplored.
  • MATERIALS AND METHODS: We evaluated seven cases of dedifferentiated liposarcomas (DDLS) and compared those with seven well-differentiated liposarcomas (WDLS).
  • RESULTS: Two out of 7 (30%) DDLS showed focal weak immunoreactivity with c-kit; no (0%) WDLS stained with c-kit.
  • Seven out of 7 (100%) DDLS showed an allelic variation in exon 10, with a single base pair substitution (A >C) at codon 541; 3/7 (43%) WDLS showed the same change.
  • [MeSH-major] Liposarcoma / enzymology. Liposarcoma / pathology. Proto-Oncogene Proteins c-kit / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158966.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA046934-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


96. Yan J, Jiao Y, Jiao F, Stuart J, Donahue LR, Beamer WG, Li X, Roe BA, LeDoux MS, Gu W: Effects of carbonic anhydrase VIII deficiency on cerebellar gene expression profiles in the wdl mouse. Neurosci Lett; 2007 Feb 21;413(3):196-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of carbonic anhydrase VIII deficiency on cerebellar gene expression profiles in the wdl mouse.
  • Recently, the waddles (wdl) mouse was identified as a carbonic anhydrase VIII (Car8) mutant.
  • To help unravel the molecular aberrations contributing to motor dysfunction in wdl mice, cerebellar gene expression profiles were examined in the mutants and their wild-type littermates.
  • Genes involved in signaling, cell division, zinc ion-binding, synapse integrity and plasticity were downregulated in wdl mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53491-7 [15466411.001]
  • [Cites] Cell. 2001 Mar 23;104(6):923-35 [11290329.001]
  • [Cites] J Cell Biol. 2005 May 23;169(4):657-67 [15911880.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):24363-70 [15863513.001]
  • [Cites] Nat Neurosci. 2005 Nov;8(11):1534-41 [16234806.001]
  • [Cites] Neurobiol Dis. 2005 Dec;20(3):673-84 [15967669.001]
  • [Cites] Genetics. 2005 Nov;171(3):1239-46 [16118194.001]
  • [Cites] Neurobiol Dis. 2006 May;22(2):302-11 [16442805.001]
  • [Cites] J Neurol Sci. 2006 Jul 15;246(1-2):21-30 [16545397.001]
  • [Cites] Cell. 2000 May 26;101(5):485-98 [10850491.001]
  • [Cites] J Neurosci. 2000 Sep 1;20(17):6333-9 [10964938.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Jul 29;355(1399):965-70 [11128990.001]
  • [Cites] Cerebellum. 2003;2(4):242-62 [14964684.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):15142-52 [14739275.001]
  • [Cites] J Neurosci. 2004 Apr 28;24(17):4187-96 [15115814.001]
  • [Cites] Thromb Haemost. 2004 May;91(5):959-66 [15116257.001]
  • [Cites] Curr Opin Neurobiol. 2004 Jun;14(3):297-304 [15194109.001]
  • [Cites] Neurosci Lett. 2004 Jul 1;364(2):67-70 [15196679.001]
  • [Cites] Nat Rev Neurosci. 2004 Aug;5(8):641-55 [15263894.001]
  • [Cites] Neurosci Res. 2004 Sep;50(1):13-22 [15288494.001]
  • [Cites] J Neurosci. 1984 Aug;4(8):1925-32 [6470761.001]
  • [Cites] Mov Disord. 1990;5(4):286-93 [2259352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4769-73 [1374913.001]
  • [Cites] Exp Gerontol. 1992;27(1):29-49 [1499683.001]
  • [Cites] Nature. 1993 Aug 19;364(6439):732-4 [8355790.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):12888-92 [8175705.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2357-60 [7964758.001]
  • [Cites] Neuron. 1995 Mar;14(3):519-26 [7695898.001]
  • [Cites] Neurochem Int. 1995 Jul;27(1):1-22 [7655341.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):88-92 [11343119.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):184-8 [11586299.001]
  • [Cites] Biochem J. 2002 May 1;363(Pt 3):599-608 [11964161.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3454-63 [12093746.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27494-500 [12011096.001]
  • [Cites] J Comp Neurol. 2003 Jun 16;461(1):31-48 [12722103.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):435-41 [12611586.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Feb 20;148(2):169-77 [14766194.001]
  • [Cites] Eur J Cell Biol. 1996 Mar;69(3):214-23 [8900486.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):284-93 [9412507.001]
  • [Cites] J Neurosci. 1998 Apr 15;18(8):2822-33 [9525999.001]
  • [Cites] Neuron. 1998 Jul;21(1):13-26 [9697848.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):87-91 [9731539.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5298-308 [9736609.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Oct 1;60(2):282-90 [9757064.001]
  • [Cites] Cell. 1998 Oct 2;95(1):17-27 [9778244.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11854-9 [10518540.001]
  • [Cites] EMBO J. 2001 Apr 2;20(7):1605-19 [11285225.001]
  • [Cites] Nat Neurosci. 2005 Apr;8(4):435-42 [15768038.001]
  • (PMID = 17174474.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR01183; United States / NINDS NIH HHS / NS / R03 NS050185; United States / NIAMS NIH HHS / AR / R01 AR051190; United States / NCRR NIH HHS / RR / P40 RR001183; United States / NINDS NIH HHS / NS / R03NS050185; United States / NIAMS NIH HHS / AR / R01AR51190; United States / NINDS NIH HHS / NS / R01NS048458; United States / NINDS NIH HHS / NS / R01 NS048458
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 4.2.1.- / Carbonic Anhydrase III
  • [Other-IDs] NLM/ NIHMS18866; NLM/ PMC1865515
  •  go-up   go-down


97. Kubo T, Sugita T, Shimose S, Arihiro K, Ochi M: Conservative surgery for well-differentiated liposarcomas of the extremities adjacent to major neurovascular structures. Surg Oncol; 2006 Nov;15(3):167-71
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgery for well-differentiated liposarcomas of the extremities adjacent to major neurovascular structures.
  • BACKGROUND: There is no clear consensus as to the appropriate nomenclature and the best surgical strategy for well-differentiated liposarcomas.
  • A wide surgical excision is recommended over marginal resection for local control of well-differentiated liposarcomas.
  • METHODS: Between 1998 and 2004, 12 well-differentiated liposarcomas of the extremities were treated at our institute.
  • CONCLUSIONS: Our findings suggested that well-differentiated liposarcomas frequently arise in close proximity to major nerves or blood vessels.
  • [MeSH-major] Extremities / blood supply. Extremities / innervation. Liposarcoma / surgery. Postoperative Complications / prevention & control. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184990.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


98. Chan WY, McHenry ID, Carter LM, Reall G, Wales CJ: Gingival liposarcoma: an unusual polyp. Br J Oral Maxillofac Surg; 2008 Mar;46(2):150-1
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival liposarcoma: an unusual polyp.
  • Liposarcomas account for up to 20% of all soft tissue tumours.
  • Sarcomas of the oral region (excluding lymphoma) account for 5% of all oral cancers, of which 10% are liposarcomas.
  • The prognosis of liposarcoma is dependant on the histopathologic type, location, and adequacy of surgical treatment.
  • Well-differentiated types have a good prognosis and minimal metastatic potential.
  • We report a case of well-differentiated liposarcoma (lipoma-like subtype), that presented as a gingival polyp.
  • [MeSH-major] Gingival Neoplasms / pathology. Liposarcoma / pathology. Polyps / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284338.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


99. Agabiti S, Gurrera A, Amico P, Vasquez E, Magro G: [Mammary hamartoma with atypical stromal cells: a potential diagnostic dilemma]. Pathologica; 2007 Dec;99(6):434-7
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mammary hamartoma with atypical stromal cells: a potential diagnostic dilemma].
  • Although atypical stromal cell (ASCs) can be encountered in several benign and malignant breast lesions, their occurrence in hamartoma has not been reported to date.
  • The authors report a case of breast hamartoma containing numerous atypical mono- or multinucleated stromal cells within the fibro-fatty component.
  • This unusual feature raised differential diagnostic problems with pleomorphic lipoma, well-differentiated liposarcoma and malignant phylloid tumour with a lipomatous heterologous component.
  • [MeSH-minor] Antigens, CD34 / analysis. Biomarkers. Breast Neoplasms / diagnosis. Diagnosis, Differential. Female. Fibroblasts / chemistry. Fibroblasts / pathology. Humans. Lipoma / diagnosis. Liposarcoma / diagnosis. Middle Aged. Phyllodes Tumor / diagnosis. Stromal Cells / chemistry. Stromal Cells / pathology. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416336.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Vimentin
  •  go-up   go-down


100. Moritani N, Yamada T, Mizobuchi K, Wakimoto M, Ikeya Y, Matsumura T, Mishima K, Iida S: Atypical lipomatous tumor of the tongue: report of a case. Acta Med Okayama; 2010 Aug;64(4):257-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lipomatous tumor of the tongue: report of a case.
  • The term atypical lipomatous tumor (ALT) is synonymous with well-differentiated liposarcoma (WDL).
  • This tumor occurs very rarely in the tongue.
  • Although recurrence of ALT/WDL is thought to be unlikely after complete excision, long-term follow-up is necessary when considering the pathologic conditions of this tumor at other sites.
  • A 68-year-old man was referred to our hospital because of a tumor on the left side of his tongue.
  • Upon palpation, the tumor was 12mm in diameter, circumscribed, elastic and hard, well demarcated, movable, and painless.
  • We diagnosed the lesion as a lipoma and extirpated the tumor under local anesthesia.
  • Because the specimen was histopathologically diagnosed as an ALT, as a precaution, we excised an additional 5mm from the area surrounding the original tumor under general anesthesia.
  • [MeSH-major] Liposarcoma / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Lipoma / diagnosis. Lipoma / pathology. Male. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802543.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement